mitomycin has been researched along with Colorectal Cancer in 368 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 9.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer." | 9.12 | The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study. ( Craddock, L; Darby, A; Geldart, T; Iveson, A; Iveson, T; Michels, J; Richardson, L, 2006) |
| "Aim of this study was to evaluate the activity of a combination regimen of chemotherapy containing mitomycin C (MMC) and etoposide (ETO) in advanced colorectal carcinoma." | 9.12 | Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy. ( Cicconetti, F; Franchi, F; Iascone, C; Ielapi, T; Nigita, G; Pastore, C; Seminara, P, 2007) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 9.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)." | 9.11 | Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004) |
| "A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%." | 9.11 | Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study. ( Bernardeschi, P; Cantore, M; De Simone, M; Dentico, P; Fiorentini, G; Guadagni, S; Poddie, DB; Rossi, G; Rossi, S; Tumolo, S; Valori, VM, 2004) |
| "The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)." | 9.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against metastatic colorectal cancer." | 9.11 | Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. ( Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N, 2005) |
| "The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area." | 9.10 | [Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 9.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "Both mitomycin C combination regimens seem to provide an acceptable therapeutic index in patients with fluoropyrimidine/leucovorin-pretreated metastatic colorectal cancer." | 9.10 | Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "MF (protracted infusion 5-fluorouracil (5-FU), 300 mg/m2/24 hours plus bolus mitomycin, 7 mg/m2 every 6 weeks, maximum 4 doses), was recently shown in a randomised trial to be superior to protracted 5-FU alone, as first-line chemotherapy for metastatic colorectal cancer (Ross et al." | 9.09 | Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. ( Chester, JD; Dent, JT; Ride, E; Seymour, MT; Wilson, G, 2000) |
| "We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer." | 9.09 | [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000) |
| "The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy." | 9.09 | Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 9.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 9.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection." | 9.08 | Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "We evaluated the technical feasibility of isolated liver perfusion (ILP) in the treatment of patients with colorectal cancer metastases confined to the liver, and investigated whether ILP allows exposure of the tumor to high concentrations of mitomycin C (MMC)." | 9.08 | Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. ( Beerman, H; de Brauw, LM; Keizer, HJ; Marinelli, A; Tjaden, UR; van Bockel, JH; van de Velde, CJ, 1996) |
| "Mitomycin C has been found clinically useful in the treatment of colorectal cancer when administered via the hepatic artery." | 9.08 | Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer. ( Kairaluoma, M; Kantola, R; Kiviniemi, H; Laitinen, S; Leinonen, S; Mäkelä, J; Siniluoto, T; Tikkakoski, T, 1997) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 9.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential." | 9.07 | Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. ( Baker, L; Gullo, JJ; Leming, PD; Lokich, JJ; LoRusso, P; McCulloch, W; Poplin, EA; Schein, P; Schulz, JJ; Veach, SR, 1994) |
| "Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver." | 9.07 | Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991) |
| "An overview of the clinical trials where mitomycin has been used in combination with modern compounds in the various settings of metastatic colorectal cancer." | 8.86 | Is there a role for mitomycin C in metastatic colorectal cancer? ( Dimou, A; Saif, MW; Syrigos, KN, 2010) |
| " Mitomycin C (MMC) is frequently used but not devoid of toxicity, of which the most common and feared is neutropenia." | 7.81 | Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. ( Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 7.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| " No studies however, have investigated the potential modulatory role of resveratrol (RV) on mitomycin C (MMC)-mediated effects on colorectal cancer." | 7.80 | Resveratrol enhances mitomycin C-mediated suppression of human colorectal cancer cell proliferation by up-regulation of p21WAF1/CIP1. ( Ali, I; Braun, DP, 2014) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 7.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 7.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients." | 7.76 | Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010) |
| "Fluorouracil-based chemotherapy, such as that with 5-fluorouracil (5-FU)/leucovorin, is standard as first-line chemotherapy for advanced colorectal cancer (CRC) in Japan." | 7.73 | In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer. ( Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K, 2005) |
| "To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer." | 7.73 | 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. ( Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T, 2006) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 7.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002." | 7.72 | Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. ( Fleming, RA; Geisinger, KR; Hawksworth, J; Levine, EA; Loggie, BW; Lovato, J; Shen, P, 2004) |
| "The clinical efficacy and safety of irinotecan (CPT-11) therapy were studied retrospectively in patients with fluoropyrimidine-resistant advanced colorectal cancer." | 7.72 | [Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer]. ( Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kubo, Y; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tsuzuki, T; Tubouchi, E, 2004) |
| "We histologically examined the effect of hepatic arterial infusion of degradable starch microspheres mixed with adriamycin and mitomycin C (DSM therapy) for liver metastases of colorectal cancer." | 7.72 | [Histological examination of the effect of hepatic arterial infusion of degradable starch microspheres mixed with adriamycin and mitomycin C for liver metastases of colorectal cancer--second report]. ( Hashimoto, D; Hoshino, T; Ishida, H; Mastumoto, Y; Miura, T; Ohsawa, T; Osada, H; Takeuchi, I; Yokoyama, M, 2004) |
| "Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer." | 7.71 | Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002) |
| "mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer." | 7.71 | [Audit of the safety of hepatic arterial infusion of degradable starch microspheres (DSM). Adriamycin (ADM).mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer]. ( Hashimoto, D; Ishida, H; Kashimada, A; Kuwabara, K; Matumoto, Y; Miura, T; Osada, H; Takeuchi, I, 2002) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 7.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "Little is known about the histological effect of hepatic arterial infusion with degradable starch microspheres (DSM), adriamycin (ADM), and mitomycin C (MMC) on liver metastasis of colorectal cancer." | 7.71 | [Histological evaluation of liver metastasis of colorectal cancer following hepatic arterial infusion with degradable starch microspheres and adriamycin/mitomycin C]. ( Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Ohsawa, T; Takeuchi, I, 2001) |
| " hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer." | 7.69 | Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. ( Arnold, MW; Dumond, D; Martin, EW; Schneebaum, S; Staubus, A; Young, DC, 1996) |
| "5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone." | 7.69 | 5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997) |
| "This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon." | 7.68 | Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. ( Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993) |
| "Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals." | 7.67 | Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989) |
| " We determined the increase in antineoplastic activities of mitomycin C (MMC) and carboquone (CQ) against human tumor cells under conditions of in vitro hypoxia, with the following results." | 7.67 | Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro. ( Kusumoto, T; Maehara, Y; Sakaguchi, Y; Saku, M; Sugimachi, K, 1989) |
| " The correlation between clinical and pharmacokinetic parameters was statistically analyzed." | 6.94 | Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. ( Amitay, Y; Gabizon, AA; Geva, R; Golan, T; Ohana, P; Perets, R; Shmeeda, H; Tahover, E, 2020) |
| "This phase II prospective study investigates possible benefits of radiofrequency ablation (RFA) combined with hepatic arterial chemoembolization using degradable starch microsphere (DSM) mixed with mitomycin C (MMC) in non-surgical candidates with colorectal liver metastases." | 6.84 | Radiofrequency Ablation Combined with Hepatic Arterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Liver Metastasis from Colorectal Cancer: A Prospective Multicenter Study. ( Hayashi, S; Inaba, Y; Nakatsuka, A; Nobata, K; Sato, Y; Takaki, H; Yamakado, K; Yamanaka, T; Yasumoto, T, 2017) |
| "We investigated 17 colorectal cancer patients' PyNPase and DPD activities in tumor and normal tissues using an enzyme-linked immunosorbent assay (ELISA) to assess their clinical significance as indicators for selecting colorectal cancer patients for 5'-DFUR together with MMC as adjuvant chemotherapy." | 6.73 | Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. ( Higashijima, J; Kurita, N; Miyamoto, H; Miyatani, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2007) |
| " However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen." | 6.69 | Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. ( Braybrooke, JP; Dixon, RM; Ganesan, TS; Harris, AL; Levitt, NC; Littlewood, TJ; O'Byrne, K; Propper, DJ; Rajagopalan, B; Talbot, DC; Thompson, CH, 2000) |
| "In an attempt to improve tumor response and survival among patients with colorectal cancer metastases confined to the liver, we developed an experimental (rats and pigs) and clinical isolated hepatic perfusion (IHP) technique to exploit maximally the steep dose-response relation of may anticancer drugs." | 6.40 | Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. ( Marinelli, A; Vahrmeijer, AL; van de Velde, CJ, 1998) |
| "A total of 124 colorectal cancer patients who underwent CRS with HIPEC between March 2015 and January 2019 were evaluated." | 5.72 | Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis. ( Baik, SH; Jeon, Y; Kang, J; Lee, HW; Lee, SJ; Park, EJ, 2022) |
| "Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 5.48 | Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018) |
| "Compare long-term outcomes in colorectal cancer (CRC) patients with peritoneal carcinomatosis (PC) treated with peritonectomy/HIPEC using oxaliplatin versus MMC." | 5.46 | Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. ( Huo, YR; Leung, V; Liauw, W; Morris, DL, 2017) |
| "Mitomycin C (MMC) has been widely used in this context, and despite good tolerability, there are doubts regarding its true benefit." | 5.38 | A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. ( Costa, FP; Ferrarotto, R; Hoff, PM; Kopetz, S; Machado, K; Mak, MP; Overman, MJ; Shah, N; Takahashi, TK, 2012) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 5.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 5.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| " Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- ." | 5.14 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. ( al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW, 2009) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "Stages I-III colorectal cancer patients (n = 753) were randomized to receive either surgery alone (control arm), surgery plus postoperative portal venous infusion of 5-FU 500 mg/m(2) plus heparin given for 24 hours for seven consecutive days plus mitomycin C 10 mg/m(2) given on the first day (arm 2), or surgery and the same chemotherapy regimen administered by peripheral venous route (arm 3)." | 5.13 | Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. ( Aeberhard, P; Harder, F; Herrmann, R; Laffer, U; Lorenz, M; Maibach, R; Metzger, U; Zuber, M, 2008) |
| "To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer." | 5.12 | The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study. ( Craddock, L; Darby, A; Geldart, T; Iveson, A; Iveson, T; Michels, J; Richardson, L, 2006) |
| "This study provides strong arguments indicating that IPCH with oxaliplatin is better tolerated than EPIC with mitomycin C and 5-FU, and is twice as efficient in curing residual peritoneal carcinomatosis measuring less than 1 mm." | 5.12 | Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. ( Benizri, E; Di Pietrantonio, D; Elias, D; Malka, D; Menegon, P; Raynard, B, 2007) |
| "Aim of this study was to evaluate the activity of a combination regimen of chemotherapy containing mitomycin C (MMC) and etoposide (ETO) in advanced colorectal carcinoma." | 5.12 | Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy. ( Cicconetti, F; Franchi, F; Iascone, C; Ielapi, T; Nigita, G; Pastore, C; Seminara, P, 2007) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 5.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)." | 5.11 | Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004) |
| "A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%." | 5.11 | Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study. ( Bernardeschi, P; Cantore, M; De Simone, M; Dentico, P; Fiorentini, G; Guadagni, S; Poddie, DB; Rossi, G; Rossi, S; Tumolo, S; Valori, VM, 2004) |
| "The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)." | 5.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against metastatic colorectal cancer." | 5.11 | Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. ( Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N, 2005) |
| "The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area." | 5.10 | [Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 5.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil." | 5.10 | Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. ( Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K, 2003) |
| "We examined the relationship between host as well as tumor factors and postoperative survival rate in patients who received combination therapy of mitomycin C + fluoropyrimidine oral antineoplastics + protein-bound polysaccharide K (PSK) (MFP therapy) after curative resection of colorectal cancer." | 5.10 | Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival. ( Abe, J; Asada, Y; Fujisawa, K; Iida, Y; Kasahara, Y; Mitsui, T; Miura, S; Munemoto, Y; Saito, H, 2002) |
| "Both mitomycin C combination regimens seem to provide an acceptable therapeutic index in patients with fluoropyrimidine/leucovorin-pretreated metastatic colorectal cancer." | 5.10 | Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "MF (protracted infusion 5-fluorouracil (5-FU), 300 mg/m2/24 hours plus bolus mitomycin, 7 mg/m2 every 6 weeks, maximum 4 doses), was recently shown in a randomised trial to be superior to protracted 5-FU alone, as first-line chemotherapy for metastatic colorectal cancer (Ross et al." | 5.09 | Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. ( Chester, JD; Dent, JT; Ride, E; Seymour, MT; Wilson, G, 2000) |
| "We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer." | 5.09 | [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000) |
| "In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer." | 5.09 | Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000) |
| "The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy." | 5.09 | Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 5.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "We conducted a multi-center study to investigate the usefulness of a combination drug therapy with doxifluridine (5'-DFUR) and mitomycin C (MMC) in colorectal cancer patients with lung metastasis." | 5.09 | [Combination chemotherapy of doxifluridine plus mitomycin C for colorectal lung metastasis--phase II study]. ( Fujita, H; Hiki, Y; Ike, H; Mitomi, T; Otani, Y; Oya, K; Sadahiro, S; Shimada, H; Yamaguchi, S, 2001) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 5.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "From May 1988 to June 1992, 129 eligible patients suffering from measurable advanced colorectal cancer were enrolled in a randomized study comparing bolus fluorouracil plus leucovorin (FU-FA); continuous fluorouracil infusion (FU-cont); FUcont plus cyclophosphamide and mitomycin C (FUMIC)." | 5.08 | A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. ( Bonnel, C; Caudry, M; Caudry, Y; Dujols, JP; Floquet, A; Marsault, C; Maton, O; Pujol, J; Quétin, P; Skawinski, P, 1995) |
| "A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection." | 5.08 | Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "A combined phase I/II study (UFTM) of tegafururacil (UFT) and mitomycin C (MMC) was performed to find the optimal dosage for advanced colorectal cancer." | 5.08 | [Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer ( Ikeda, E; Isomoto, H; Kato, T; Kodaira, S; Okuda, M; Takahashi, T; Teramoto, T; Yamamoto, Y, 1996) |
| " The pharmacokinetics of mitomycin C (MMC) were investigated in 12 colorectal cancer patients with liver metastases undergoing chemoembolisation." | 5.08 | Pharmacokinetics of intraarterial mitomycin C in the chemoembolisation treatment of liver metastases. ( Biederbick, W; Botvinik-Helling, S; Fischbach, R; Heindel, W; Klaus, W; Lackner, K; Rump, AF; Schierholz, JM; Stemmler, M; Theisohn, M, 1996) |
| "We evaluated the technical feasibility of isolated liver perfusion (ILP) in the treatment of patients with colorectal cancer metastases confined to the liver, and investigated whether ILP allows exposure of the tumor to high concentrations of mitomycin C (MMC)." | 5.08 | Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. ( Beerman, H; de Brauw, LM; Keizer, HJ; Marinelli, A; Tjaden, UR; van Bockel, JH; van de Velde, CJ, 1996) |
| "Mitomycin C has been found clinically useful in the treatment of colorectal cancer when administered via the hepatic artery." | 5.08 | Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer. ( Kairaluoma, M; Kantola, R; Kiviniemi, H; Laitinen, S; Leinonen, S; Mäkelä, J; Siniluoto, T; Tikkakoski, T, 1997) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 5.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "The aim of this study was to evaluate the efficacy and tolerance of second-line continuous 5-fluorouracil (5FU) chemotherapy combined with folinic acid and mitomycin C in patients with advanced colorectal cancer who progressed on first-line chemotherapy." | 5.08 | 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. ( Bardou, VJ; Bernardini, D; Capodano, G; Giovannini, M; Perrier, H; Seitz, JF, 1998) |
| "The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential." | 5.07 | Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. ( Baker, L; Gullo, JJ; Leming, PD; Lokich, JJ; LoRusso, P; McCulloch, W; Poplin, EA; Schein, P; Schulz, JJ; Veach, SR, 1994) |
| "A prospective, controlled randomized trial of hepatic arterial infusion of 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin C (MMC) [FAM group] versus 5-FU, epirubicin (EPIR) and MMC [FEM group] in patients with unresectable liver metastasis from colorectal cancer is reported." | 5.07 | [A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group]. ( Kunii, Y; Mashiko, H; Momono, S; Muto, I; Nakagawa, K; Ouchi, A; Shiiba, K; Wada, M; Yamamoto, K; Yamazaki, T, 1993) |
| "Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver." | 5.07 | Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991) |
| "An overview of the clinical trials where mitomycin has been used in combination with modern compounds in the various settings of metastatic colorectal cancer." | 4.86 | Is there a role for mitomycin C in metastatic colorectal cancer? ( Dimou, A; Saif, MW; Syrigos, KN, 2010) |
| "The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years." | 4.84 | First-line therapeutic strategies in metastatic colorectal cancer. ( Davies, JM; Goldberg, RM, 2008) |
| "The synergism between oxaliplatin and 5-fluorouracil (5FU)/leucovorin in the treatment of colorectal cancer raises the prospect of further clinically effective combinations." | 4.82 | New oxaliplatin-based combinations in the treatment of colorectal cancer. ( Cassidy, J; Hochster, H, 2003) |
| " Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer." | 4.80 | [Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998) |
| "We undertook a meta-analysis to assess the effects on recurrence and survival of administering fluorouracil (5-FU)-based chemotherapy by PVI after colorectal cancer surgery." | 4.79 | Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. ( , 1997) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Mitomycin C-IPC after CRS was associated with better survival outcomes than CRS alone in patients with resectable peritoneal metastasis of colorectal cancer." | 4.31 | Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis. ( Baek, JH; Choi, GS; Kang, BW; Kim, CH; Kim, HJ; Kim, HR; Kim, JG; Kim, YJ; Park, JS; Park, SY, 2023) |
| " More than 50% of centers administer oxaliplatin (74%), or mitomycin-C (65%) in colorectal cancer; cisplatin in gastric cancer (73%) and mesothelioma (74%)." | 3.88 | Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. ( Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ, 2018) |
| "To examine the effect of radiation on in vitro drug activation and release of Promitil, a pegylated liposomal formulation of a mitomycin C (MMC) lipid-based prodrug; and examine the efficacy and toxicity of Promitil with concurrent radiation in colorectal cancer models." | 3.83 | Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. ( Caster, JM; Gabizon, AA; Ohana, P; Tian, X; Wagner, KT; Wang, AZ; Warner, SB; Zhang, T, 2016) |
| " Mitomycin C (MMC) is frequently used but not devoid of toxicity, of which the most common and feared is neutropenia." | 3.81 | Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. ( Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015) |
| " This study demonstrates that the combination of the chemotherapeutic agent mitomycin C with the proteasome inhibitor bortezomib induced synergistic cytotoxicity and apoptosis, which was even more effective under hypoxia in colorectal cancer cells." | 3.81 | Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53. ( Bartlett, DL; Choudry, HA; Dilly, AK; Kwon, YT; Lee, YJ; Song, X, 2015) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 3.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| " No studies however, have investigated the potential modulatory role of resveratrol (RV) on mitomycin C (MMC)-mediated effects on colorectal cancer." | 3.80 | Resveratrol enhances mitomycin C-mediated suppression of human colorectal cancer cell proliferation by up-regulation of p21WAF1/CIP1. ( Ali, I; Braun, DP, 2014) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 3.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "Although peritoneal carcinomatosis (PC) from colorectal and appendiceal tumors is consistent with metastatic disease, complete cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) using mitomycin C (MMC) can improve survival." | 3.79 | A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. ( Ihemelandu, C; Levine, EA; Russell, G; Shen, P; Stewart, J; Votanopoulos, K, 2013) |
| "FOLFOXIRI demonstrated higher efficacy compared to 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer." | 3.78 | Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. ( Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E, 2012) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 3.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom." | 3.76 | Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010) |
| "The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients." | 3.76 | Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010) |
| "To construct a new target-oriented conjugate of humanized carcinoembryonic antigen (CEA) specific single chain variable fragment (scFv) and mitomycin (MMC) against colorectal cancer, and to investigate its influence on the growth and apoptosis of colorectal cancer cells." | 3.74 | Construction of humanized carcinoembryonic antigen specific single chain variable fragment and mitomycin conjugate. ( Chen, DJ; Chen, F; Du, T; Tan, Z, 2007) |
| "Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperatively; 5-fluorouracil early post-operatively) for peritoneal carcinomatosis from colorectal cancer from 1996 to 2003 were evaluated retrospectively." | 3.73 | Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005) |
| "Fluorouracil-based chemotherapy, such as that with 5-fluorouracil (5-FU)/leucovorin, is standard as first-line chemotherapy for advanced colorectal cancer (CRC) in Japan." | 3.73 | In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer. ( Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K, 2005) |
| "To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer." | 3.73 | 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. ( Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T, 2006) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 3.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "The significance of hepatic arterial infusion chemotherapy for unresectable liver metastases from colorectal cancer was evaluated in 50 patients, who received either of the following regimens: 1 shot 5-FU + epirubicin + MMC (FAM group); hepatic arterial infusion of 5-FU for 2 hours + MMC (MF group); hepatic arterial infusion of 5-FU for 2 hours (5-FU group)." | 3.72 | [Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer]. ( Hirakawa, K; Kosaka, K; Nishihara, T; Nishino, H; Ohira, M; Yamada, N, 2003) |
| "We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002." | 3.72 | Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. ( Fleming, RA; Geisinger, KR; Hawksworth, J; Levine, EA; Loggie, BW; Lovato, J; Shen, P, 2004) |
| "The clinical efficacy and safety of irinotecan (CPT-11) therapy were studied retrospectively in patients with fluoropyrimidine-resistant advanced colorectal cancer." | 3.72 | [Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer]. ( Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kubo, Y; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tsuzuki, T; Tubouchi, E, 2004) |
| "We histologically examined the effect of hepatic arterial infusion of degradable starch microspheres mixed with adriamycin and mitomycin C (DSM therapy) for liver metastases of colorectal cancer." | 3.72 | [Histological examination of the effect of hepatic arterial infusion of degradable starch microspheres mixed with adriamycin and mitomycin C for liver metastases of colorectal cancer--second report]. ( Hashimoto, D; Hoshino, T; Ishida, H; Mastumoto, Y; Miura, T; Ohsawa, T; Osada, H; Takeuchi, I; Yokoyama, M, 2004) |
| "Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer." | 3.71 | Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002) |
| "mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer." | 3.71 | [Audit of the safety of hepatic arterial infusion of degradable starch microspheres (DSM). Adriamycin (ADM).mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer]. ( Hashimoto, D; Ishida, H; Kashimada, A; Kuwabara, K; Matumoto, Y; Miura, T; Osada, H; Takeuchi, I, 2002) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 3.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "Adjuvant chemotherapy with 5-fluorouracil (5-FU) and mitomycin C (MMC) has commonly been used after resection of colorectal cancer." | 3.71 | The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer. ( Hashimoto, Y; Minami, K; Ueda, K; Watatani, M, 2001) |
| "Little is known about the histological effect of hepatic arterial infusion with degradable starch microspheres (DSM), adriamycin (ADM), and mitomycin C (MMC) on liver metastasis of colorectal cancer." | 3.71 | [Histological evaluation of liver metastasis of colorectal cancer following hepatic arterial infusion with degradable starch microspheres and adriamycin/mitomycin C]. ( Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Ohsawa, T; Takeuchi, I, 2001) |
| "To apply (HIPEC) using mitomycin in patients with peritoneal carcinomatosis." | 3.70 | [Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute]. ( Beijnen, JH; Boot, H; Kaag, MM; van der Vange, N; Witkamp, AJ; Zoetmulder, FA, 1999) |
| " We present herein the cases of three patients with multiple liver metastases from colorectal cancer in whom complete remission was achieved by treatment with an HAI of IL-2 in combination with mitomycin C (MMC) and 5-fluorouracil (5-FU)." | 3.69 | Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases. ( Akabane, Y; Koh, K; Kurooka, K; Nakajima, I; Ohnishi, H; Okuno, K; Shindo, K; Yasutomi, M, 1994) |
| " hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer." | 3.69 | Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. ( Arnold, MW; Dumond, D; Martin, EW; Schneebaum, S; Staubus, A; Young, DC, 1996) |
| "We determined the chemosensitivity for cisplatin, mitomycin C, adriamycin, and 5-fluorouracil in vitro in 93 fresh human colorectal cancers using the MTT assay and performed chemotherapy according to results of the MTT assay." | 3.69 | Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. ( Hotta, T; Ishimoto, K; Iwahashi, M; Murakami, K; Nakamori, M; Noguchi, K; Tani, M; Tanimura, H; Yamaue, H, 1996) |
| "5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone." | 3.69 | 5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997) |
| " In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial." | 3.69 | Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995) |
| "This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon." | 3.68 | Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. ( Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993) |
| "A total of 77 patients with advanced colorectal cancer, including postoperative patients with liver, lung and peritoneal metastases, were treated with single or multiple injections of monoclonal antibody A7-neocarzinostatin (A7-NCS)." | 3.68 | Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer. ( Honda, M; Kitamura, K; Noguchi, A; Otsuji, E; Takahashi, T; Yamaguchi, T, 1993) |
| "Immediately before closing the abdomen in a curative operation for colorectal cancer, 20 mg of Mitomycin C (MMC) was administered by intravenous, intraperitoneal or intrapelvic routes, and portal blood and peripheral blood were simultaneously collected to investigate the disposition of MMC." | 3.68 | [Concentration of mitomycin C in portal blood and peripheral blood after intra venous, intraperitoneal or intrapelvic administration]. ( Ohtsuka, K; Ono, K; Sato, Y, 1993) |
| "Twenty-four patients with advanced colorectal cancer received two cycles of combination chemotherapy consisting of mitomycin 10 mg/m2 for 5 days continuous infusion and allopurinol 300 mg x 3/day p." | 3.68 | Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity. ( Karvounis, N; Kosmidis, P; Tsavaris, N; Tzannou, I, 1992) |
| "Eighty-seven colorectal adenocarcinomas from untreated patients were investigated by short term tumor cultures to test in vitro sensitivity to 5-fluorouracil and mitomycin C." | 3.68 | 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. ( Barone, C; Codacci-Pisanelli, G; Codacci-Pisanelli, M; Ferri, GM; Franchi, F; Garufi, C; Grieco, A; Pagani, V; Seminara, P, 1991) |
| "The effects of oxygen concentration on the chemosensitivity of mouse sarcoma-180 (S-180) cells and human colorectal cancer tissues to mitomycin C (MMC) or carboquone (CQ) were determined in vitro, since evidence had been obtained that these drugs are more effective in HeLa cells." | 3.68 | Sarcoma-180 cells and human colorectal tumor cells under in vitro hypoxic conditions are more sensitive to mitomycin C and carboquone. ( Emi, Y; Kohnoe, S; Kusumoto, T; Maehara, Y; Sakaguchi, Y; Sugimachi, K, 1991) |
| "Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals." | 3.67 | Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989) |
| " We determined the increase in antineoplastic activities of mitomycin C (MMC) and carboquone (CQ) against human tumor cells under conditions of in vitro hypoxia, with the following results." | 3.67 | Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro. ( Kusumoto, T; Maehara, Y; Sakaguchi, Y; Saku, M; Sugimachi, K, 1989) |
| "Survival of patients affected by colorectal cancer peritoneal metastases (CRC-PM) can be improved with combined complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 3.11 | Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C. ( Brigand, C; Delhorme, JB; Diab, S; Liu, D; Rohr, S; Romain, B; Sauvinet, G; Séverac, F, 2022) |
| " The correlation between clinical and pharmacokinetic parameters was statistically analyzed." | 2.94 | Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. ( Amitay, Y; Gabizon, AA; Geva, R; Golan, T; Ohana, P; Perets, R; Shmeeda, H; Tahover, E, 2020) |
| "The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate." | 2.87 | MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. ( Alabiso, I; Alabiso, O; Baratelli, C; Brizzi, MP; Di Maio, M; Forti, L; Ottone, A; Scagliotti, GV; Sonetto, C; Tampellini, M, 2018) |
| "This phase II prospective study investigates possible benefits of radiofrequency ablation (RFA) combined with hepatic arterial chemoembolization using degradable starch microsphere (DSM) mixed with mitomycin C (MMC) in non-surgical candidates with colorectal liver metastases." | 2.84 | Radiofrequency Ablation Combined with Hepatic Arterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Liver Metastasis from Colorectal Cancer: A Prospective Multicenter Study. ( Hayashi, S; Inaba, Y; Nakatsuka, A; Nobata, K; Sato, Y; Takaki, H; Yamakado, K; Yamanaka, T; Yasumoto, T, 2017) |
| "Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CRC) because conventional treatment modalities could not produce significant survival benefit, which highlights the acute need for new treatment strategies." | 2.79 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center. ( Huang, CQ; Li, Y; Liu, Y; Wu, HT; Yang, XJ; Yonemura, Y; Yu, Y, 2014) |
| "We investigated 17 colorectal cancer patients' PyNPase and DPD activities in tumor and normal tissues using an enzyme-linked immunosorbent assay (ELISA) to assess their clinical significance as indicators for selecting colorectal cancer patients for 5'-DFUR together with MMC as adjuvant chemotherapy." | 2.73 | Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. ( Higashijima, J; Kurita, N; Miyamoto, H; Miyatani, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2007) |
| "Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group)." | 2.72 | Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer. ( Chang, HM; Ha, HK; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, KH; Lee, MG; Ryu, MH; Yu, CS, 2006) |
| " In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)." | 2.71 | Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. ( Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004) |
| "Peritoneal carcinomatosis of colorectal cancer is probably best treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 2.71 | Long-term survival of peritoneal carcinomatosis of colorectal origin. ( Boot, H; van Ruth, S; van Slooten, G; Verwaal, VJ; Witkamp, A; Zoetmulder, FA, 2005) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | 2.70 | Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| " However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen." | 2.69 | Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. ( Braybrooke, JP; Dixon, RM; Ganesan, TS; Harris, AL; Levitt, NC; Littlewood, TJ; O'Byrne, K; Propper, DJ; Rajagopalan, B; Talbot, DC; Thompson, CH, 2000) |
| " We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer." | 2.69 | UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca. ( Jakobsen, A, 2000) |
| "There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer." | 2.68 | Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995) |
| " Pharmacokinetic data from these patients showed very low plasma levels both for KW-2149, as for both known metabolites M-16 and M-18." | 2.68 | Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion. ( Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Tranchand, B; Van Oosterom, A; Verdonk, R, 1995) |
| "Twenty-one stomach cancer patients and 34 colorectal cancer patients were registered in the study." | 2.67 | [Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)]. ( Hachisuka, K; Honda, H; Honda, K; Maeda, A; Nakazato, H; Tsuruga, N; Yamaguchi, A; Yoshizaki, S; Yura, J, 1994) |
| "Ninety-six patients with colorectal cancer (stage B2-C) were randomized to the control arm or to receive adjuvant chemotherapy with folinic acid, FU and MMC." | 2.67 | 5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. ( Astone, A; Barone, C; Cassano, A; Coco, C; Franchi, F; Netri, G; Pozzo, C; Ratto, C; Ricevuto, E; Sofo, L, 1991) |
| "After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy." | 2.67 | [Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]. ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990) |
| "Resectability of liver-limited colorectal cancer metastases should be considered as an endpoint for all patients." | 2.44 | Regional chemotherapy for liver-limited metastatic colorectal cancer. ( Healey-Bird, BR; Kemeny, NE; Power, DG, 2008) |
| "Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice." | 2.41 | [Progress in adjuvant therapy for colorectal cancer]. ( Kakeji, Y; Kohnoe, S; Maehara, Y, 2002) |
| "In an attempt to improve tumor response and survival among patients with colorectal cancer metastases confined to the liver, we developed an experimental (rats and pigs) and clinical isolated hepatic perfusion (IHP) technique to exploit maximally the steep dose-response relation of may anticancer drugs." | 2.40 | Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. ( Marinelli, A; Vahrmeijer, AL; van de Velde, CJ, 1998) |
| "A total of 124 colorectal cancer patients who underwent CRS with HIPEC between March 2015 and January 2019 were evaluated." | 1.72 | Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis. ( Baik, SH; Jeon, Y; Kang, J; Lee, HW; Lee, SJ; Park, EJ, 2022) |
| "Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mutBRAF) or KRAS mutation (mutKRAS) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal metastasis (PM) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been less investigated." | 1.72 | Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. ( Dagenborg, VJ; Dueland, S; Flatmark, K; Goscinski, MA; Hofsli, E; Larsen, SG; Lund-Iversen, M; Sorbye, H; Steigen, SE; Torgunrud, A, 2022) |
| "Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis." | 1.62 | Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO ( Abatini, C; Attalla El Halabieh, M; Di Giorgio, A; Lodoli, C; Pacelli, F; Rotolo, S; Santullo, F, 2021) |
| "Mitomycin-C (MMC) was used in 20% and oxaliplatin in 10%." | 1.56 | Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. ( Ashwin, KR; Kumar C, R; Rauthan, A; Somashekhar, SP; Yethadka, R; Zaveri, S, 2020) |
| "Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 1.48 | Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018) |
| "Compare long-term outcomes in colorectal cancer (CRC) patients with peritoneal carcinomatosis (PC) treated with peritonectomy/HIPEC using oxaliplatin versus MMC." | 1.46 | Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. ( Huo, YR; Leung, V; Liauw, W; Morris, DL, 2017) |
| "Weight loss was common after HIPEC as 38 of 41 patients demonstrated weight loss." | 1.43 | Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates. ( Beaty, KA; Dineen, SP; Fournier, KF; Mansfield, PF; Rafeeq, S; Robinson, KA; Roland, CL; Royal, RE, 2016) |
| "In Taiwan, colorectal cancer with peritoneal carcinomatosis is considered a terminal condition." | 1.43 | Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. ( Chen, CH; Hsieh, MC; Lin, EK; Lu, YJ; Wu, SY, 2016) |
| "In patients undergoing colorectal cancer surgery, skeletal muscle depletion (sarcopenia) is associated with impaired postoperative recovery and decreased survival." | 1.42 | Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. ( Boerma, D; Bollen, TL; Braam, HJ; de Hingh, IH; van Oudheusden, TR; van Ramshorst, B; van Vugt, JL; Vestering, A; Wiezer, MJ, 2015) |
| "Mitomycin C (88." | 1.40 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. ( Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ, 2014) |
| "Long-term OS after CRS and HIPEC for colorectal cancer is associated with CC and neoadjuvant therapy containing bevacizumab." | 1.40 | Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. ( Ceelen, W; Pattyn, P; Putte, DV; Van Nieuwenhove, Y, 2014) |
| "Treatment of peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is relatively ineffective and associated with morbidity." | 1.40 | Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis. ( Bemelman, WA; Buskens, CJ; Crezee, J; Gardenbroek, TJ; Punt, CJ; Sloothaak, DA; Tanis, PJ, 2014) |
| "Among the CRC and appendiceal cancer group the median overall survival was 20." | 1.40 | [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin]. ( Aderka, D; Berger, Y; Brenner, B; Golan, T; Gutman, M; Lebedyev, A; Levi, Y; Natur, M; Nevler, A; Purim, O; Zbar, AP, 2014) |
| "Patients with PC from colorectal or appendiceal cancer, pseudomyxoma peritonei or malignant peritoneal mesothelioma referred to the single national HIPEC centre were prospectively registered from June 2006 to July 2012." | 1.39 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. ( Hagemann-Madsen, R; Iversen, LH; Laurberg, S; Rasmussen, PC, 2013) |
| " Diffuse colorectal carcinomatosis was generated in mice prior to intraperitoneal lavage with mitomycin C (MMC) at clinically comparable dosing for variable lengths of time." | 1.39 | The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. ( Attwood, K; Camoriano, M; Francescutti, V; Haslinger, M; Kane, JM; Kim, M; Rivera, L; Seshadri, M; Skitzki, JJ, 2013) |
| "Mitomycin C (MMC) has been widely used in this context, and despite good tolerability, there are doubts regarding its true benefit." | 1.38 | A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. ( Costa, FP; Ferrarotto, R; Hoff, PM; Kopetz, S; Machado, K; Mak, MP; Overman, MJ; Shah, N; Takahashi, TK, 2012) |
| "Nu/Nu mice were injected IP with HT-29 colorectal cancer cells." | 1.36 | Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. ( Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK, 2010) |
| "In patients with colorectal cancer peritoneal carcinomatosis (CRPC), only patients with a complete cytoreduction will benefit." | 1.36 | Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. ( Chua, TC; Esquivel, J; Morris, DL, 2010) |
| "Mitomycin was the most frequently active agent for the superficial part." | 1.35 | In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA). ( Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH, 2009) |
| "To assess the effect of transcatheter arterial chemoembolization (TACE) combined with laser-induced thermotherapy (LITT) for treatment of liver metastases in an animal model." | 1.33 | Liver metastases in rats: chemoembolization combined with interstitial laser ablation for treatment. ( Bechstein, WO; Khan, MF; Maataoui, A; Mack, MG; Oppermann, E; Qian, J; Roozru, M; Schmidt, S; Vogl, TJ, 2005) |
| "Hemoptysis was negligible until he died 8 months later." | 1.32 | [Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases]. ( Ishigaki, T; Kitai, T; Kojima, N; Miki, A; Nishikawa, S; Nomura, A; Todo, G; Ukikusa, M, 2003) |
| " The observed concentration-time profiles were used to develop a population pharmacokinetic model using nonlinear mixed-effect modelling (NONMEM)." | 1.32 | Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. ( Beijnen, JH; Mathôt, RA; Sparidans, RW; van Ruth, S; Verwaal, VJ; Zoetmulder, FA, 2004) |
| "Colorectal cancer with peritoneal carcinomatosis is usually considered incurable." | 1.32 | Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. ( Cotte, E; Gilly, FN; Glehen, O; Sayag-Beaujard, AC; Schreiber, V; Vignal, J, 2004) |
| " MMC was assayed by high-pressure liquid chromatography (HPLC), and pharmacokinetic parameters were determined using an open, two-compartment model and linear kinetics." | 1.31 | Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases. ( Cerretani, D; Civeli, L; Correale, P; De Manzoni, G; Francini, G; Giorgi, G; Marrelli, D; Pieraccini, M; Pinto, E; Roviello, F, 2002) |
| "Data on 45 patients with colorectal cancer were analyzed." | 1.31 | Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. ( Hinoshita, E; Kinukawa, N; Kuwano, M; Maehara, Y; Sugimachi, K; Taguchi, K; Tsuneyoshi, M; Uchiumi, T, 2000) |
| "A total of 35 patients with primary colorectal cancer who underwent surgical treatment were examined by chemosensitivity test with the viable tumor samples using Histoculture Drug Response Assay (HDRA)." | 1.31 | [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer]. ( Imaseki, H; Isono, K; Iwasaki, K; Kondo, S; Kouno, T; Makino, H; Nakajima, K; Natsume, T; Ochiai, T; Okazumi, S; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 2000) |
| "The aim of this study was to evaluate the clinical effectiveness of intra-arterial chemotherapy combined with degradable starch microspheres (DSM) for liver metastases and the possibility of predicting the effectiveness of the chemotherapy by pretreatment diagnostic imaging." | 1.31 | [Clinical effectiveness of intra-arterial chemotherapy combined with degradable starch microspheres (DSM) for liver metastases and prediction of effectiveness by diagnostic imaging]. ( Majima, T; Nakajima, T; Nozu, S; Okayasu, K; Saitou, AY; Yagi, A, 2001) |
| "Eleven colorectal cancer patients underwent hepatic resection for liver metastasis." | 1.30 | [Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis]. ( Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Murata, K; Nakano, H; Ohigashi, H; Sasaki, Y; Tsugawa, T; Yasuda, T, 1998) |
| "Three patients with colorectal cancer and pulmonary metastasis who had previously undergone surgical treatment, were treated by combination chemotherapy with CDDP and 5-FU regimen, but the growth of the metastatic tumor could not be controlled finally." | 1.30 | [Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC]. ( Horie, H; Hosoya, Y; Ishizuka, T; Kanazawa, K; Kashiwagi, H; Kojima, M; Konishi, H; Shitou, K, 1998) |
| "A total of 22 patients with primary colorectal cancer who underwent surgical treatment were examined for chemosensitivity with iable tumor samples using the Histoculture Drug Response Assay (HDRA)." | 1.30 | Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. ( Hayashi, H; Imaseki, H; Isono, K; Nakajima, K; Ochiai, T; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 1999) |
| "Two cases of hepatic metastasis of colorectal cancer were treated effectively by intrahepatic-arterial infusion immunotherapy using OK-432 (2 KE/week or 2 weeks), recombinant IL-2 (35 x 10(4) JRU or 40 x 10(4) JRU/week or 2 weeks), MMC (4 mg/week or 2 weeks) and 5-FU (250 mg/day during admission, 250 mg/week or 2 weeks during outpatient treatment)." | 1.29 | [Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Kurosaka, Y; Matsushita, M; Takashima, S; Tomita, F, 1994) |
| " These results provide a rationale for using short duration of FUdR in combination with other drugs." | 1.29 | Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance. ( Arisawa, Y; Dalton, RR; Sigurdson, ER; Sutanto-Ward, E, 1994) |
| "Since 1980, 89 patients with colorectal cancer showed liver metastasis." | 1.29 | [Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer]. ( Akaike, M; Okamoto, T; Sugimasa, Y; Takemiya, S, 1993) |
| "There were 43 colorectal and 104 appendiceal cancer patients." | 1.29 | Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Chang, D; Koslowe, P; Sugarbaker, PH, 1996) |
| " The method was found to be safe when flow was observed and dosage decisions were made during perfusion according to flow." | 1.29 | Peritoneal carcinomatosis and radioimmunoguided surgery. ( Arnold, MW; Martin, EW; Schneebaum, S; Staubus, AE, 1996) |
| "Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma." | 1.28 | [Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma]. ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992) |
| " In this study, the pharmacokinetic profile of intrahepatic arterial mitomycin C microcapsules is reported." | 1.28 | Mitomycin C-loaded microcapsules in the treatment of colorectal liver metastases. Pharmacokinetics of regionally administered particulate chemotherapy. ( Blackie, R; Goldberg, JA; Kato, T; Kerr, DJ; McArdle, CS; Pettit, L; Whately, TL, 1991) |
| "Chemotherapy for colorectal cancer with liver metastases following surgical operation for primary tumor should be selected following surgical intervention." | 1.28 | [Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases]. ( Ishida, Y; Kojima, N; Kusumoto, S; Nakayoshi, A; Oka, H, 1991) |
| "With colorectal cancer, the therapeutic outcome for multiple hepatic metastasis extending to the bilateral lobe, even when various chemotherapies are administered, is extremely poor." | 1.28 | [Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer]. ( Gotohda, H; Katoh, M; Kinami, Y; Kumaki, T; Saitoh, H; Takashima, S; Takegawa, S; Tomita, F, 1991) |
| "Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection." | 1.28 | Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. ( Furusawa, M; Kakeji, Y; Maehara, Y; Sugimachi, K; Tomoda, H; Tsujitani, S; Watanabe, A, 1991) |
| "The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations." | 1.28 | [Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1990) |
| "These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "For seventy two patients with liver metastasis, radical surgery with removal of liver metastatic lesions post removed intra arterial infusion therapy (5FU,MMC) was carried out and the resulting 5-year survival rate was 40% for patients with H1 liver metastasis." | 1.28 | [Surgery for far-advanced colorectal cancer--extension of surgical indication and its results]. ( Hojo, K, 1989) |
| "Lipiodol-ADM was injected for hepatocellular carcinoma every 2 months and MMC-5-FU was injected for liver metastasis of colorectal carcinoma every one or two weeks." | 1.28 | [Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma]. ( Adachi, W; Hanasaki, K; Horigome, N; Iida, F; Kajikawa, S; Kinosita, T; Kuroda, T; Sodeyama, H, 1989) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 1.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (6.52) | 18.7374 |
| 1990's | 120 (32.61) | 18.2507 |
| 2000's | 104 (28.26) | 29.6817 |
| 2010's | 82 (22.28) | 24.3611 |
| 2020's | 38 (10.33) | 2.80 |
| Authors | Studies |
|---|---|
| Parikh, MS | 1 |
| Johnson, P | 1 |
| Romanes, JP | 1 |
| Freitag, HE | 1 |
| Spring, ME | 1 |
| Garcia-Henriquez, N | 1 |
| Monson, JRT | 1 |
| Lee, SJ | 1 |
| Jeon, Y | 1 |
| Lee, HW | 1 |
| Kang, J | 1 |
| Baik, SH | 1 |
| Park, EJ | 1 |
| Larsen, SG | 3 |
| Goscinski, MA | 1 |
| Dueland, S | 3 |
| Steigen, SE | 1 |
| Hofsli, E | 1 |
| Torgunrud, A | 1 |
| Lund-Iversen, M | 1 |
| Dagenborg, VJ | 1 |
| Flatmark, K | 3 |
| Sorbye, H | 1 |
| El-Sayes, N | 1 |
| Vito, A | 1 |
| Salem, O | 1 |
| Workenhe, ST | 1 |
| Wan, Y | 1 |
| Mossman, K | 1 |
| Sugarbaker, PH | 10 |
| Delhorme, JB | 1 |
| Sauvinet, G | 1 |
| Séverac, F | 1 |
| Diab, S | 1 |
| Liu, D | 1 |
| Rohr, S | 1 |
| Romain, B | 2 |
| Brigand, C | 2 |
| Mangieri, CW | 2 |
| Valenzuela, CD | 2 |
| Solsky, IB | 2 |
| Erali, RA | 2 |
| Votanopoulos, KI | 2 |
| Shen, P | 5 |
| Levine, EA | 5 |
| Park, SY | 2 |
| Park, JS | 2 |
| Kim, HJ | 2 |
| Kim, JG | 2 |
| Kang, BW | 2 |
| Baek, JH | 2 |
| Kim, HR | 2 |
| Kim, CH | 2 |
| Kim, YJ | 2 |
| Choi, GS | 2 |
| Geva, R | 2 |
| Alon, G | 1 |
| Nathanson, M | 1 |
| Bar-David, S | 2 |
| Nevo, N | 2 |
| Aizic, A | 1 |
| Peles-Avraham, S | 1 |
| Lahat, G | 2 |
| Nizri, E | 2 |
| Lee Goldstein, A | 1 |
| Abu-Abeid, A | 1 |
| Dayan, D | 1 |
| Xie, L | 1 |
| Cheng, L | 2 |
| Wei, Y | 1 |
| Hassan, S | 1 |
| Dritsas, S | 1 |
| O'Dwyer, ST | 1 |
| Aziz, O | 1 |
| Sutton, P | 1 |
| Wang, X | 1 |
| Fish, R | 1 |
| Wintjens, AGWE | 1 |
| Liu, H | 1 |
| Fransen, PKH | 1 |
| Lenaerts, K | 1 |
| van Almen, GC | 1 |
| Gijbels, MJ | 1 |
| Hadfoune, M | 1 |
| Boonen, BTC | 1 |
| Lieuwes, NG | 1 |
| Biemans, R | 1 |
| Dubois, LJ | 1 |
| Dankers, PYW | 1 |
| de Hingh, IHJT | 6 |
| Bouvy, ND | 1 |
| Hübner, M | 2 |
| van Der Speeten, K | 3 |
| Govaerts, K | 1 |
| de Hingh, I | 2 |
| Villeneuve, L | 1 |
| Kusamura, S | 5 |
| Glehen, O | 7 |
| Wisselink, DD | 1 |
| Braakhuis, LLF | 1 |
| Gallo, G | 1 |
| van Grevenstein, WMU | 3 |
| van Dieren, S | 1 |
| Kok, NFM | 4 |
| de Reuver, PR | 4 |
| Tanis, PJ | 5 |
| Koh, CE | 1 |
| Ansari, N | 1 |
| Morris, D | 2 |
| Moran, B | 4 |
| Somashekhar, SP | 2 |
| Yethadka, R | 1 |
| Kumar C, R | 1 |
| Ashwin, KR | 1 |
| Zaveri, S | 1 |
| Rauthan, A | 1 |
| Baratti, D | 5 |
| Azmi, N | 1 |
| Guaglio, M | 2 |
| Montenovo, M | 2 |
| Deraco, M | 7 |
| Narasimhan, V | 1 |
| Warrier, S | 1 |
| Michael, M | 1 |
| Ramsay, R | 1 |
| Heriot, A | 1 |
| Hentzen, JEKR | 1 |
| van der Plas, WY | 2 |
| Kuipers, H | 1 |
| Ramcharan, S | 1 |
| Been, LB | 1 |
| Hoogwater, FJH | 1 |
| van Ginkel, RJ | 2 |
| van Dam, GM | 1 |
| Hemmer, PHJ | 3 |
| Kruijff, S | 3 |
| Elekonawo, FMK | 1 |
| van Eden, WJ | 2 |
| Ewalds, RSG | 1 |
| de Jong, LAW | 1 |
| Bremers, AJA | 2 |
| Aalbers, AGJ | 3 |
| Gabizon, AA | 2 |
| Tahover, E | 1 |
| Golan, T | 2 |
| Perets, R | 1 |
| Amitay, Y | 1 |
| Shmeeda, H | 1 |
| Ohana, P | 2 |
| Sammartino, P | 2 |
| Ansaloni, L | 1 |
| Asero, S | 1 |
| Baiocchi, G | 1 |
| Bagnoli, P | 1 |
| Cavaliere, D | 1 |
| Framarini, M | 1 |
| Cirocchi, R | 1 |
| Coccolini, F | 1 |
| Decian, F | 1 |
| Delrio, P | 1 |
| Sassaroli, C | 1 |
| De Simone, M | 3 |
| Robella, M | 2 |
| Vaira, M | 2 |
| Di Giorgio, A | 2 |
| Fagotti, A | 1 |
| Lorusso, D | 1 |
| Federici, O | 1 |
| Fiorentini, G | 3 |
| Fambrini, M | 1 |
| Scaringi, S | 1 |
| Garofalo, A | 1 |
| Valle, M | 1 |
| Gelmini, R | 1 |
| Cabry, F | 1 |
| Cautero, N | 1 |
| Sorrentino, L | 1 |
| Graziosi, L | 1 |
| Bartolini, V | 1 |
| Lippolis, PV | 1 |
| Macrì, A | 1 |
| Pasqual, EM | 1 |
| Roviello, F | 2 |
| Marrelli, D | 2 |
| Orsenigo, E | 1 |
| Sommariva, A | 2 |
| Bakkers, C | 2 |
| van Erning, FN | 1 |
| Rovers, KP | 3 |
| Nienhuijs, SW | 3 |
| Burger, JW | 1 |
| Lemmens, VE | 1 |
| Aalbers, AG | 2 |
| Kok, NF | 1 |
| Boerma, D | 3 |
| Brandt, AR | 1 |
| Hemmer, PH | 1 |
| van Grevenstein, WM | 1 |
| Tuynman, JB | 2 |
| de Hingh, IH | 6 |
| Hulshof, EC | 1 |
| Lurvink, RJ | 2 |
| Caserta, N | 1 |
| van Wezel, T | 1 |
| Böhringer, S | 1 |
| Swen, JJ | 1 |
| Gelderblom, H | 1 |
| Guchelaar, HJ | 1 |
| Deenen, MJ | 1 |
| Helderman, RFCPA | 1 |
| Löke, DR | 1 |
| Verhoeff, J | 1 |
| Rodermond, HM | 1 |
| van Bochove, GGW | 1 |
| Boon, M | 1 |
| van Kesteren, S | 1 |
| Garcia Vallejo, JJ | 1 |
| Kok, HP | 1 |
| Franken, NAP | 1 |
| Crezee, J | 2 |
| Oei, AL | 1 |
| Zhang, X | 2 |
| Wu, Q | 1 |
| Wei, M | 1 |
| Deng, X | 1 |
| Gu, C | 1 |
| Wang, Z | 1 |
| Lo Dico, R | 1 |
| Faron, M | 1 |
| Yonemura, Y | 7 |
| Pocard, M | 2 |
| Sardi, A | 3 |
| Liberale, G | 1 |
| Kartheuser, A | 2 |
| Sugarbaker, P | 1 |
| Ceelen, W | 3 |
| Quenet, F | 1 |
| Sideris, L | 2 |
| Goere, D | 3 |
| Limbert, M | 1 |
| Nagourney, RA | 1 |
| Evans, S | 1 |
| Tran, PH | 1 |
| Nagourney, AJ | 1 |
| García-Olmo, D | 1 |
| Villarejo Campos, P | 1 |
| Barambio, J | 1 |
| Gomez-Heras, SG | 1 |
| Vega-Clemente, L | 1 |
| Olmedillas-Lopez, S | 1 |
| Guadalajara, H | 1 |
| Garcia-Arranz, M | 1 |
| Loaec, C | 1 |
| Guérin-Charbonnel, C | 1 |
| Vignaud, T | 1 |
| Paineau, J | 1 |
| Thibaudeau, E | 1 |
| Dumont, F | 2 |
| Chen, L | 1 |
| Chen, Q | 1 |
| Wu, Y | 2 |
| Zhu, M | 1 |
| Hu, J | 1 |
| Zhuang, Z | 1 |
| Benzaquen, E | 1 |
| Wang, Y | 1 |
| Wiseman, S | 1 |
| Rosenfeld, V | 1 |
| Dubé, P | 1 |
| Pelletier, JS | 1 |
| Vanounou, T | 1 |
| Taibi, A | 1 |
| Perrin, ML | 1 |
| Albouys, J | 1 |
| Jacques, J | 1 |
| Yardin, C | 1 |
| Durand-Fontanier, S | 1 |
| Bardet, SM | 1 |
| Rotolo, S | 1 |
| Santullo, F | 1 |
| Attalla El Halabieh, M | 1 |
| Lodoli, C | 1 |
| Abatini, C | 1 |
| Pacelli, F | 1 |
| Prabhu, A | 1 |
| Brandl, A | 1 |
| Wakama, S | 1 |
| Sako, S | 1 |
| Ishibashi, H | 2 |
| Mizumoto, A | 1 |
| Takao, N | 1 |
| Ichinose, M | 1 |
| Motoi, S | 1 |
| Liu, Y | 2 |
| Burger, JWA | 1 |
| Creemers, GM | 1 |
| Thijs, AMJ | 1 |
| Brandt-Kerkhof, ARM | 1 |
| Madsen, EVE | 1 |
| van Meerten, E | 1 |
| Kusters, M | 1 |
| Versteeg, KS | 1 |
| Buffart, TE | 1 |
| Wiezer, MJ | 3 |
| Los, M | 1 |
| Verheul, HMW | 1 |
| de Groot, DJA | 1 |
| Witkamp, AJ | 3 |
| Koopman, M | 1 |
| Nederend, J | 1 |
| Lahaye, MJ | 1 |
| Kranenburg, O | 2 |
| Fijneman, RJA | 1 |
| van 't Erve, I | 1 |
| Snaebjornsson, P | 1 |
| Dijkgraaf, MGW | 1 |
| Punt, CJA | 1 |
| van de Vlasakker, VCJ | 1 |
| Cashin, PH | 1 |
| González-Moreno, S | 2 |
| Lehmann, K | 1 |
| Li, Y | 3 |
| Morris, DL | 6 |
| Piso, P | 2 |
| Quadros, CA | 1 |
| Rau, B | 1 |
| Spiliotis, J | 2 |
| Teo, MCC | 2 |
| Verwaal, VJ | 5 |
| Gayarre, J | 1 |
| Martín-Gimeno, P | 1 |
| Osorio, A | 1 |
| Paumard, B | 1 |
| Barroso, A | 1 |
| Fernández, V | 1 |
| de la Hoya, M | 1 |
| Rojo, A | 1 |
| Caldés, T | 1 |
| Palacios, J | 1 |
| Urioste, M | 1 |
| Benítez, J | 1 |
| García, MJ | 1 |
| Lev, A | 1 |
| Deihimi, S | 1 |
| Shagisultanova, E | 1 |
| Xiu, J | 1 |
| Lulla, AR | 1 |
| Dicker, DT | 1 |
| El-Deiry, WS | 1 |
| Baratelli, C | 1 |
| Tampellini, M | 1 |
| Di Maio, M | 1 |
| Ottone, A | 1 |
| Brizzi, MP | 1 |
| Forti, L | 1 |
| Alabiso, I | 1 |
| Sonetto, C | 1 |
| Alabiso, O | 1 |
| Scagliotti, GV | 1 |
| Pernot, S | 1 |
| Velut, G | 1 |
| Kourie, RH | 1 |
| Amouyal, G | 1 |
| Sapoval, M | 1 |
| Pointet, AL | 1 |
| Landi, B | 1 |
| Zaimi, Y | 1 |
| Lepère, C | 1 |
| Pellerin, O | 1 |
| Taieb, J | 1 |
| Morales-Soriano, R | 1 |
| Esteve-Pérez, N | 1 |
| Segura-Sampedro, JJ | 1 |
| Cascales-Campos, P | 1 |
| Barrios, P | 2 |
| Woensdregt, K | 1 |
| Huitema, ADR | 1 |
| Boot, H | 4 |
| Kozman, MA | 1 |
| Fisher, OM | 1 |
| Rebolledo, BJ | 1 |
| Parikh, R | 1 |
| Valle, SJ | 1 |
| Arrowaili, A | 1 |
| Alzahrani, N | 1 |
| Liauw, W | 2 |
| Arjona-Sánchez, A | 1 |
| Boldo-Roda, E | 1 |
| Camps, B | 1 |
| Carrasco-Campos, J | 1 |
| Concepción Martín, V | 1 |
| García-Fadrique, A | 1 |
| Gutiérrez-Calvo, A | 1 |
| Morales, R | 1 |
| Ortega-Pérez, G | 1 |
| Pérez-Viejo, E | 1 |
| Prada-Villaverde, A | 2 |
| Torres-Melero, J | 2 |
| Vicente, E | 1 |
| Villarejo-Campos, P | 1 |
| Sánchez-Hidalgo, JM | 1 |
| Casado-Adam, A | 1 |
| García-Martin, R | 1 |
| Medina, M | 1 |
| Caro, T | 1 |
| Villar, C | 1 |
| Aranda, E | 1 |
| Cano-Osuna, MT | 1 |
| Díaz-López, C | 1 |
| Torres-Tordera, E | 1 |
| Briceño-Delgado, FJ | 1 |
| Rufián-Peña, S | 1 |
| Vogl, TJ | 5 |
| Lahrsow, M | 1 |
| Albrecht, MH | 1 |
| Hammerstingl, R | 2 |
| Thompson, ZM | 1 |
| Gruber-Rouh, T | 1 |
| Mooi, JK | 1 |
| Wirapati, P | 1 |
| Asher, R | 1 |
| Lee, CK | 5 |
| Savas, P | 1 |
| Price, TJ | 9 |
| Townsend, A | 1 |
| Hardingham, J | 1 |
| Buchanan, D | 1 |
| Williams, D | 1 |
| Tejpar, S | 1 |
| Mariadason, JM | 2 |
| Tebbutt, NC | 7 |
| Mahmoud, AM | 1 |
| Ismail, YM | 1 |
| Hussien, A | 1 |
| Debaky, Y | 1 |
| Ahmed, IS | 1 |
| Mikhael, HSW | 1 |
| Moneer, M | 1 |
| Sipok, A | 1 |
| Nieroda, C | 1 |
| King, MC | 1 |
| Sittig, M | 1 |
| Gushchin, V | 1 |
| Frøysnes, IS | 2 |
| Andersson, Y | 1 |
| Davidson, B | 1 |
| Øien, JT | 1 |
| Julsrud, L | 1 |
| Fodstad, Ø | 1 |
| Ubink, I | 1 |
| Bolhaqueiro, ACF | 1 |
| Elias, SG | 1 |
| Raats, DAE | 1 |
| Constantinides, A | 1 |
| Peters, NA | 1 |
| Wassenaar, ECE | 1 |
| Laclé, MM | 1 |
| Kops, GJPL | 1 |
| Borel Rinkes, IHM | 1 |
| Shannon, NB | 1 |
| Tan, JW | 1 |
| Tan, HL | 1 |
| Wang, W | 1 |
| Chen, Y | 1 |
| Lim, HJ | 1 |
| Tan, QX | 1 |
| Hendrikson, J | 1 |
| Ng, WH | 1 |
| Loo, LY | 1 |
| Skanthakumar, T | 1 |
| Wasudevan, SD | 1 |
| Kon, OL | 1 |
| Lim, TKH | 1 |
| Tan, GHC | 1 |
| Chia, CS | 2 |
| Soo, KC | 2 |
| Ong, CJ | 1 |
| Iversen, LH | 2 |
| Rasmussen, PC | 2 |
| Hagemann-Madsen, R | 1 |
| Laurberg, S | 2 |
| Farshid, P | 1 |
| Darvishi, A | 1 |
| Naguib, N | 1 |
| Bazrafshan, B | 1 |
| Paul, J | 1 |
| Mbalisike, E | 1 |
| Cassidy, J | 1 |
| Hochster, H | 1 |
| Francescutti, V | 1 |
| Rivera, L | 1 |
| Seshadri, M | 1 |
| Kim, M | 1 |
| Haslinger, M | 1 |
| Camoriano, M | 1 |
| Attwood, K | 1 |
| Kane, JM | 1 |
| Skitzki, JJ | 1 |
| Saif, MW | 2 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Hardingham, JE | 3 |
| Townsend, AR | 3 |
| Wrin, JW | 3 |
| Wilson, K | 4 |
| Weickhardt, A | 3 |
| Simes, RJ | 2 |
| Murone, C | 3 |
| Nasyrov, AR | 1 |
| Pirtskhalava, TL | 1 |
| Korovina, IaV | 1 |
| Carter, HE | 1 |
| Zannino, D | 2 |
| John Simes, R | 1 |
| Schofield, DJ | 1 |
| Howard, K | 1 |
| Zalcberg, JR | 3 |
| Passot, G | 3 |
| Bakrin, N | 2 |
| Roux, AS | 1 |
| Vaudoyer, D | 1 |
| Gilly, FN | 3 |
| Cotte, E | 3 |
| Hompes, D | 1 |
| D'Hoore, A | 1 |
| Wolthuis, A | 1 |
| Fieuws, S | 1 |
| Mirck, B | 1 |
| Bruin, S | 1 |
| Verwaal, V | 1 |
| Shimizu, T | 4 |
| Sonoda, H | 1 |
| Murata, S | 1 |
| Takebayashi, K | 1 |
| Ohta, H | 2 |
| Miyake, T | 1 |
| Mekata, E | 1 |
| Shiomi, H | 1 |
| Naka, S | 1 |
| Tani, T | 2 |
| Tabrizian, P | 1 |
| Shrager, B | 1 |
| Jibara, G | 1 |
| Yang, MJ | 1 |
| Romanoff, A | 1 |
| Hiotis, S | 1 |
| Sarpel, U | 1 |
| Labow, DM | 1 |
| Bozkurt, O | 1 |
| Karaca, H | 1 |
| Ciltas, A | 1 |
| Kaplan, MA | 1 |
| Benekli, M | 1 |
| Sevinc, A | 1 |
| Demirci, U | 1 |
| Eren, T | 1 |
| Kodaz, H | 1 |
| Isikdogan, A | 1 |
| Ozkan, M | 1 |
| Buyukberber, S | 1 |
| Stec, R | 1 |
| Bodnar, L | 1 |
| Smoter, M | 1 |
| Korniluk, J | 1 |
| Kuchar, A | 1 |
| Młot, B | 1 |
| Szczylik, C | 1 |
| Van Nieuwenhove, Y | 1 |
| Putte, DV | 1 |
| Pattyn, P | 1 |
| Iusco, D | 1 |
| Bonomi, S | 1 |
| Grassi, A | 2 |
| Virzì, S | 1 |
| Leo, E | 1 |
| Teo, MC | 1 |
| Ching Tan, GH | 1 |
| Lim, C | 1 |
| Tham, CK | 1 |
| Sloothaak, DA | 1 |
| Gardenbroek, TJ | 1 |
| Bemelman, WA | 1 |
| Punt, CJ | 2 |
| Buskens, CJ | 1 |
| Esquivel, J | 2 |
| Lowy, AM | 1 |
| Markman, M | 1 |
| Chua, T | 1 |
| Pelz, J | 1 |
| Baumgartner, JM | 1 |
| Berri, R | 1 |
| Bretcha-Boix, P | 1 |
| Flores-Ayala, G | 1 |
| Gomez-Portilla, A | 1 |
| Goodman, M | 1 |
| Halkia, E | 1 |
| Moller, M | 1 |
| Salti, G | 1 |
| Senthil, M | 1 |
| Turaga, K | 1 |
| Trout, R | 1 |
| Berger, Y | 1 |
| Zbar, AP | 1 |
| Lebedyev, A | 1 |
| Levi, Y | 1 |
| Nevler, A | 1 |
| Aderka, D | 1 |
| Purim, O | 1 |
| Brenner, B | 1 |
| Natur, M | 1 |
| Gutman, M | 1 |
| Huang, CQ | 1 |
| Yang, XJ | 2 |
| Yu, Y | 1 |
| Wu, HT | 1 |
| Ali, I | 1 |
| Braun, DP | 1 |
| Kwakman, R | 1 |
| de Cuba, EM | 1 |
| de Winter, JP | 1 |
| Delis-van Diemen, PM | 1 |
| Tijssen, M | 1 |
| Rooimans, MA | 1 |
| Krijgsman, O | 1 |
| Carvalho, B | 1 |
| Peters, GJ | 1 |
| Bonjer, HJ | 1 |
| Meijer, GA | 1 |
| Te Velde, EA | 1 |
| van Vugt, JL | 1 |
| Braam, HJ | 1 |
| van Oudheusden, TR | 1 |
| Vestering, A | 1 |
| Bollen, TL | 1 |
| van Ramshorst, B | 2 |
| Bruhn, MA | 1 |
| Mann, KP | 1 |
| Simes, J | 2 |
| Gebski, V | 1 |
| Van Hazel, G | 1 |
| Robinson, B | 2 |
| Cunningham, D | 8 |
| Cecil, T | 1 |
| Chandrakumaran, K | 1 |
| Arnold, S | 1 |
| Mohamed, F | 2 |
| Venkatasubramaniam, A | 1 |
| Kemmel, V | 1 |
| Mercoli, HA | 1 |
| Meyer, N | 1 |
| Brumaru, D | 1 |
| Lessinger, JM | 1 |
| Weickhardt, AJ | 1 |
| Williams, DS | 1 |
| Chionh, F | 1 |
| Parry, MM | 1 |
| Asadi, K | 1 |
| Scott, AM | 1 |
| Nagtegaal, ID | 1 |
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 1 |
| Keita, H | 1 |
| Dineen, SP | 1 |
| Robinson, KA | 1 |
| Roland, CL | 1 |
| Beaty, KA | 1 |
| Rafeeq, S | 1 |
| Mansfield, PF | 1 |
| Royal, RE | 1 |
| Fournier, KF | 1 |
| Song, X | 1 |
| Dilly, AK | 1 |
| Choudry, HA | 1 |
| Bartlett, DL | 1 |
| Kwon, YT | 1 |
| Lee, YJ | 1 |
| Kuijpers, AM | 1 |
| Hauptmann, M | 1 |
| Havenga, K | 1 |
| Kosmacek, EA | 1 |
| Chatterjee, A | 1 |
| Tong, Q | 1 |
| Lin, C | 1 |
| Oberley-Deegan, RE | 1 |
| Spasojevic, M | 1 |
| Petrelli, F | 1 |
| Ghidini, A | 1 |
| Inno, A | 1 |
| Barni, S | 1 |
| Navez, J | 1 |
| Remue, C | 1 |
| Leonard, D | 1 |
| Bachmann, R | 1 |
| Hubert, C | 1 |
| Coubeau, L | 1 |
| Komuta, M | 1 |
| Van den Eynde, M | 1 |
| Zech, F | 1 |
| Jabbour, N | 1 |
| Tian, X | 1 |
| Warner, SB | 1 |
| Wagner, KT | 1 |
| Caster, JM | 1 |
| Zhang, T | 1 |
| Wang, AZ | 1 |
| Xie, BY | 1 |
| Wu, AW | 1 |
| Leung, V | 1 |
| Huo, YR | 1 |
| Yamakado, K | 1 |
| Inaba, Y | 1 |
| Sato, Y | 4 |
| Yasumoto, T | 1 |
| Hayashi, S | 1 |
| Yamanaka, T | 1 |
| Nobata, K | 1 |
| Takaki, H | 1 |
| Nakatsuka, A | 1 |
| Lin, EK | 1 |
| Hsieh, MC | 1 |
| Chen, CH | 1 |
| Lu, YJ | 1 |
| Wu, SY | 1 |
| Aghayeva, A | 1 |
| Benlice, C | 1 |
| Bilgin, IA | 1 |
| Atukeren, P | 1 |
| Dogusoy, G | 1 |
| Demir, F | 1 |
| Atasoy, D | 1 |
| Baca, B | 1 |
| Power, DG | 1 |
| Healey-Bird, BR | 1 |
| Kemeny, NE | 3 |
| Laffer, U | 7 |
| Metzger, U | 6 |
| Aeberhard, P | 4 |
| Lorenz, M | 2 |
| Harder, F | 2 |
| Maibach, R | 1 |
| Zuber, M | 1 |
| Herrmann, R | 4 |
| al-shammaa Hassan, AH | 1 |
| Yang, GL | 1 |
| Liu, SY | 1 |
| Lu, YL | 1 |
| Zhang, JW | 1 |
| Ota, K | 1 |
| Kurita, S | 1 |
| Nishimura, M | 2 |
| Ogawa, M | 1 |
| Kamei, Y | 1 |
| Imai, K | 1 |
| Ariyoshi, Y | 1 |
| Kataoka, K | 1 |
| Murakami, M | 1 |
| Oyama, A | 1 |
| Hoshino, A | 1 |
| Amo, H | 1 |
| Kato, T | 5 |
| Gruber, T | 1 |
| Balzer, JO | 1 |
| Eichler, K | 2 |
| Zangos, S | 2 |
| Davies, JM | 1 |
| Goldberg, RM | 1 |
| Cho, YB | 1 |
| Lee, WY | 1 |
| Song, SY | 1 |
| Choi, SH | 1 |
| Shin, HJ | 1 |
| Ahn, KD | 1 |
| Lee, JM | 1 |
| Kim, HC | 2 |
| Yun, SH | 1 |
| Chun, HK | 1 |
| Lanuke, K | 1 |
| Mack, LA | 2 |
| Temple, WJ | 2 |
| Varban, O | 1 |
| Stewart, JH | 1 |
| McCoy, TP | 1 |
| Loriot, Y | 1 |
| Mordant, P | 1 |
| Deutsch, E | 1 |
| Olaussen, KA | 1 |
| Soria, JC | 1 |
| Cohen, MS | 1 |
| Al-Kasspooles, MF | 1 |
| Williamson, SK | 1 |
| Henry, D | 1 |
| Broward, M | 1 |
| Roby, KF | 1 |
| Chua, TC | 2 |
| Dimou, A | 1 |
| Syrigos, KN | 1 |
| Gebski, VJ | 1 |
| Cummins, MM | 2 |
| van Hazel, GA | 1 |
| Broad, A | 1 |
| Ganju, V | 1 |
| Ackland, SP | 1 |
| Forgeson, G | 1 |
| Saunders, MP | 1 |
| Stockler, MR | 1 |
| Chua, Y | 1 |
| Shabaruddin, FH | 1 |
| Elliott, RA | 1 |
| Valle, JW | 1 |
| Newman, WG | 1 |
| Payne, K | 1 |
| Klaver, YL | 2 |
| Hendriks, T | 1 |
| Lomme, RM | 1 |
| Rutten, HJ | 1 |
| Bleichrodt, RP | 1 |
| Albert, M | 1 |
| Kiefer, MV | 1 |
| Sun, W | 1 |
| Haller, D | 1 |
| Fraker, DL | 1 |
| Tuite, CM | 1 |
| Stavropoulos, SW | 1 |
| Mondschein, JI | 1 |
| Soulen, MC | 1 |
| Noura, S | 1 |
| Ohue, M | 1 |
| Shingai, T | 1 |
| Kano, S | 1 |
| Ohigashi, H | 3 |
| Yano, M | 1 |
| Ishikawa, O | 3 |
| Takenaka, A | 1 |
| Murata, K | 2 |
| Kameyama, M | 3 |
| Stuart, OA | 1 |
| Chang, D | 2 |
| Mahteme, H | 1 |
| Kang, EJ | 1 |
| Choi, YJ | 1 |
| Kim, JS | 2 |
| Kim, ST | 1 |
| Park, KH | 1 |
| Choi, IK | 1 |
| Oh, SC | 1 |
| Seo, JH | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Tod, M | 1 |
| Steghens, A | 1 |
| Chua, A | 1 |
| Shivasami, A | 1 |
| Peeters, M | 1 |
| Price, T | 2 |
| Fornaro, L | 1 |
| Vasile, E | 1 |
| Masi, G | 1 |
| Loupakis, F | 1 |
| Baldi, GG | 1 |
| Allegrini, G | 1 |
| Salvatore, L | 1 |
| Cremolini, C | 1 |
| Cupini, S | 1 |
| Cortesi, E | 2 |
| Tuzi, A | 1 |
| Granetto, C | 1 |
| Brunetti, IM | 1 |
| Ricci, S | 2 |
| Falcone, A | 1 |
| Ito, K | 2 |
| Ito, H | 2 |
| Gonen, M | 1 |
| Allen, PJ | 1 |
| Paty, PB | 1 |
| Fong, Y | 1 |
| Dematteo, RP | 1 |
| Blumgart, LH | 1 |
| Jarnagin, WR | 1 |
| D'Angelica, MI | 1 |
| Ferrarotto, R | 1 |
| Machado, K | 1 |
| Mak, MP | 1 |
| Shah, N | 1 |
| Takahashi, TK | 1 |
| Costa, FP | 1 |
| Overman, MJ | 1 |
| Kopetz, S | 1 |
| Hoff, PM | 1 |
| Weber, T | 1 |
| Roitman, M | 1 |
| Link, KH | 4 |
| Votanopoulos, K | 1 |
| Ihemelandu, C | 1 |
| Stewart, J | 1 |
| Russell, G | 1 |
| Cui, S | 1 |
| Ba, M | 1 |
| Tang, Y | 1 |
| Liu, J | 1 |
| Wang, B | 1 |
| Tang, H | 1 |
| Zhong, S | 1 |
| Glockzin, G | 1 |
| von Breitenbuch, P | 1 |
| Schlitt, HJ | 1 |
| Yang, T | 1 |
| Fang, S | 1 |
| Zhang, HX | 1 |
| Xu, LX | 1 |
| Zhang, ZQ | 1 |
| Yuan, KT | 1 |
| Xue, CL | 1 |
| Yu, HL | 1 |
| Zhang, S | 1 |
| Li, YF | 1 |
| Shi, HP | 1 |
| Zhang, Y | 1 |
| Eveno, C | 1 |
| Dartigues, P | 1 |
| Honoré, C | 1 |
| Tzanis, D | 1 |
| Benhaim, L | 1 |
| Malka, D | 2 |
| Elias, D | 3 |
| Francois, E | 1 |
| Smith, D | 1 |
| Dahan, L | 1 |
| Michel, C | 1 |
| Perrier, H | 2 |
| Mari, V | 1 |
| Seitz, JF | 2 |
| Follana, P | 1 |
| Evesque, L | 1 |
| Chamorey, E | 1 |
| McConnell, YJ | 1 |
| Francis, WP | 1 |
| Ho, T | 1 |
| Liu, LX | 1 |
| Zhang, WH | 1 |
| Jiang, HC | 1 |
| Zhu, AL | 1 |
| Wu, LF | 1 |
| Qi, SY | 1 |
| Piao, DX | 1 |
| Mori, T | 1 |
| Fu, QG | 1 |
| Meng, FD | 1 |
| Shen, XD | 1 |
| Guo, RX | 1 |
| Kotake, K | 2 |
| Koyama, Y | 1 |
| Shida, S | 1 |
| Tajima, Y | 1 |
| Ishikawa, H | 3 |
| Kanazawa, K | 2 |
| Miyata, M | 1 |
| Nagamachi, Y | 1 |
| Iwasaki, Y | 1 |
| Omoto, R | 1 |
| Tamakuma, S | 1 |
| Kitajima, M | 1 |
| Kodaira, S | 4 |
| Takeuchi, I | 7 |
| Ishida, H | 8 |
| Kuwabara, K | 1 |
| Hashimoto, D | 7 |
| Osada, H | 4 |
| Kashimada, A | 2 |
| Matumoto, Y | 1 |
| Miura, T | 7 |
| Kohnoe, S | 3 |
| Kakeji, Y | 2 |
| Maehara, Y | 5 |
| Janciauskiene, R | 1 |
| Juozaityte, E | 1 |
| Pavalkis, D | 1 |
| Cerretani, D | 1 |
| Pieraccini, M | 1 |
| Civeli, L | 1 |
| Correale, P | 1 |
| Francini, G | 1 |
| De Manzoni, G | 1 |
| Pinto, E | 1 |
| Giorgi, G | 1 |
| Yamada, Y | 2 |
| Shirao, K | 1 |
| Hyodo, I | 2 |
| Arai, Y | 1 |
| Denda, T | 1 |
| Ambo, T | 1 |
| Ohtsu, A | 1 |
| Bamias, A | 1 |
| Papamichael, D | 1 |
| Syrigos, K | 1 |
| Pavlidis, N | 1 |
| Tokunaga, T | 1 |
| Sumimura, J | 1 |
| Yoshidome, K | 1 |
| Fujita, S | 1 |
| Tsuji, K | 1 |
| Oota, F | 1 |
| Tsuboyama, N | 1 |
| Nagai, I | 1 |
| Yeoh, C | 1 |
| Chau, I | 1 |
| Norman, AR | 4 |
| Hill, M | 2 |
| Ross, PJ | 3 |
| Maruyama, S | 1 |
| Okada, N | 2 |
| Yokoyama, M | 3 |
| Nakata, H | 1 |
| Matsumoto, Y | 3 |
| Kosaka, K | 1 |
| Nishino, H | 1 |
| Yamada, N | 1 |
| Nishihara, T | 1 |
| Ohira, M | 1 |
| Hirakawa, K | 1 |
| Mastumoto, Y | 2 |
| Kitai, T | 1 |
| Nomura, A | 1 |
| Miki, A | 1 |
| Ukikusa, M | 1 |
| Kojima, N | 2 |
| Nishikawa, S | 1 |
| Ishigaki, T | 1 |
| Todo, G | 1 |
| van Ruth, S | 2 |
| Mathôt, RA | 1 |
| Sparidans, RW | 1 |
| Beijnen, JH | 3 |
| Zoetmulder, FA | 4 |
| Hawksworth, J | 1 |
| Lovato, J | 1 |
| Loggie, BW | 1 |
| Geisinger, KR | 1 |
| Fleming, RA | 1 |
| Hickish, T | 1 |
| Tait, D | 1 |
| Ford, HE | 1 |
| Middleton, G | 1 |
| Sumpter, K | 2 |
| Oates, J | 3 |
| A'Hern, RP | 1 |
| Schreiber, V | 1 |
| Sayag-Beaujard, AC | 1 |
| Vignal, J | 1 |
| Kumada, T | 1 |
| Sone, Y | 1 |
| Toyoda, H | 1 |
| Kiriyama, S | 1 |
| Tanikawa, M | 1 |
| Hisanaga, Y | 1 |
| Kuzuya, T | 1 |
| Nonogaki, K | 1 |
| Shimizu, J | 1 |
| Yamauti, T | 1 |
| Kawase, N | 1 |
| Hildebrandt, B | 1 |
| Dräger, J | 1 |
| Kerner, T | 1 |
| Deja, M | 1 |
| Löffel, J | 1 |
| Stroszczynski, C | 1 |
| Ahlers, O | 1 |
| Felix, R | 1 |
| Riess, H | 1 |
| Wust, P | 1 |
| Gyldenkerne, N | 1 |
| Glimelius, B | 1 |
| Frödin, JE | 1 |
| Kjaer, M | 1 |
| Pfeiffer, P | 1 |
| Hansen, F | 1 |
| Keldsen, N | 1 |
| Sandberg, E | 1 |
| Jakobsen, A | 2 |
| Strocchi, E | 1 |
| Iaffaioli, RV | 1 |
| Facchini, G | 1 |
| Mantovani, G | 1 |
| Cavallo, G | 1 |
| Tortoriello, A | 1 |
| D'Angelo, R | 1 |
| Formato, R | 1 |
| Rosato, G | 1 |
| Fiore, F | 1 |
| Iaccarino, V | 1 |
| Petrella, G | 1 |
| Memoli, B | 1 |
| Santangelo, M | 1 |
| Camaggi, CM | 1 |
| Rao, S | 2 |
| Hill, ME | 2 |
| Tebbutt, N | 2 |
| Shellito, P | 1 |
| Nishina, T | 1 |
| Moriwaki, T | 1 |
| Kajiwara, T | 1 |
| Tsuzuki, T | 1 |
| Hirao, K | 1 |
| Tubouchi, E | 1 |
| Nasu, J | 1 |
| Hirasaki, S | 1 |
| Masumoto, T | 1 |
| Kubo, Y | 1 |
| Kurita, A | 1 |
| Shirakawa, K | 1 |
| Nakada, H | 3 |
| Ohsawa, T | 3 |
| Hayashi, Y | 1 |
| Inokuma, S | 3 |
| Hoshino, T | 2 |
| Assisi, D | 1 |
| La Penta, R | 1 |
| Stigliano, V | 1 |
| Greco, C | 1 |
| Cianciulli, AM | 1 |
| Giannarelli, D | 3 |
| Casale, V | 1 |
| Poddie, DB | 1 |
| Cantore, M | 2 |
| Rossi, S | 1 |
| Tumolo, S | 1 |
| Dentico, P | 1 |
| Bernardeschi, P | 1 |
| Guadagni, S | 2 |
| Rossi, G | 1 |
| Valori, VM | 1 |
| Kecmanovic, DM | 1 |
| Pavlov, MJ | 1 |
| Ceranic, MS | 1 |
| Sepetkovski, AV | 1 |
| Kovacevic, PA | 1 |
| Stamenkovic, AB | 1 |
| Lim, DH | 1 |
| Park, YS | 1 |
| Park, BB | 1 |
| Ji, SH | 1 |
| Lee, J | 1 |
| Park, KW | 1 |
| Kang, JH | 1 |
| Lee, SH | 1 |
| Park, JO | 1 |
| Kim, K | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Witkamp, A | 1 |
| van Slooten, G | 1 |
| Storojeva, I | 1 |
| Boulay, JL | 1 |
| Heinimann, K | 1 |
| Ballabeni, P | 1 |
| Terracciano, L | 1 |
| Mild, G | 1 |
| Rochlitz, C | 1 |
| Sawada, T | 4 |
| Hirose, K | 1 |
| Chong, G | 1 |
| Dickson, JL | 1 |
| Brennan, DD | 1 |
| Farrelly, C | 1 |
| Cooney, R | 1 |
| Norris, S | 1 |
| McEniff, N | 1 |
| Trerotola, SO | 1 |
| Maataoui, A | 1 |
| Qian, J | 1 |
| Mack, MG | 1 |
| Khan, MF | 1 |
| Oppermann, E | 1 |
| Roozru, M | 1 |
| Schmidt, S | 1 |
| Bechstein, WO | 1 |
| Yamashita, K | 1 |
| Urakami, A | 1 |
| Kubozoe, T | 1 |
| Ikeda, M | 2 |
| Hirabayashi, Y | 1 |
| Yamamura, M | 1 |
| Iki, K | 1 |
| Akiyama, T | 2 |
| Matsumoto, H | 1 |
| Hirai, T | 2 |
| Sadahira, Y | 1 |
| Tsunoda, T | 1 |
| Alliot, C | 1 |
| Kim, JC | 1 |
| Lee, KH | 1 |
| Yu, CS | 1 |
| Kim, TW | 1 |
| Chang, HM | 1 |
| Ryu, MH | 1 |
| Kim, JH | 1 |
| Ha, HK | 1 |
| Lee, MG | 1 |
| Cavaliere, F | 2 |
| Perri, P | 2 |
| Rossi, CR | 1 |
| Pilati, PL | 1 |
| Aloe, S | 1 |
| Di Filippo, S | 1 |
| Di Filippo, F | 2 |
| Yan, TD | 2 |
| Chu, F | 1 |
| Links, M | 1 |
| Kam, PC | 1 |
| Glenn, D | 1 |
| Michels, J | 1 |
| Geldart, T | 1 |
| Darby, A | 1 |
| Craddock, L | 1 |
| Iveson, A | 1 |
| Richardson, L | 1 |
| Iveson, T | 1 |
| Benizri, E | 1 |
| Di Pietrantonio, D | 1 |
| Menegon, P | 1 |
| Raynard, B | 1 |
| da Silva, RG | 1 |
| Aphinives, P | 1 |
| Bhudhisawasdi, V | 1 |
| Sae-seow, O | 1 |
| Uttaravichien, T | 1 |
| Seminara, P | 3 |
| Pastore, C | 1 |
| Iascone, C | 1 |
| Cicconetti, F | 1 |
| Nigita, G | 1 |
| Ielapi, T | 1 |
| Franchi, F | 4 |
| Bijelic, L | 1 |
| Nishioka, M | 1 |
| Miyamoto, H | 1 |
| Kurita, N | 1 |
| Higashijima, J | 1 |
| Yoshikawa, K | 1 |
| Miyatani, T | 1 |
| Shimada, M | 1 |
| Selby, JB | 1 |
| Bauer, RW | 1 |
| Chen, DJ | 1 |
| Tan, Z | 1 |
| Chen, F | 1 |
| Du, T | 1 |
| Chouillard, E | 1 |
| Ata, T | 1 |
| De Jonghe, B | 1 |
| Maggiori, L | 1 |
| Helmy, N | 1 |
| Coscas, Y | 1 |
| Outin, H | 1 |
| Hanada, H | 1 |
| Umekita, N | 1 |
| Maeshiro, T | 1 |
| Miyamoto, S | 1 |
| Yamada, F | 1 |
| Awane, Y | 1 |
| Kohashi, S | 1 |
| Shiroto, H | 1 |
| Kondo, M | 3 |
| Takahashi, N | 1 |
| Shinohara, T | 1 |
| Ikuta, K | 1 |
| Yamada, S | 1 |
| Uchino, J | 1 |
| Furukawa, Y | 1 |
| Otani, Y | 2 |
| Ihara, A | 1 |
| Tsuji, R | 1 |
| Okamura, R | 1 |
| Sato, K | 2 |
| Hiki, Y | 2 |
| Shinohara, K | 1 |
| Conti, JA | 1 |
| Saltz, LB | 1 |
| André, AM | 1 |
| Grossano, DD | 1 |
| Bertino, JR | 1 |
| Riesener, KP | 2 |
| Winkeltau, G | 2 |
| Klemm, M | 1 |
| Schumpelick, V | 2 |
| Jablonski, KA | 1 |
| Caudry, M | 1 |
| Bonnel, C | 1 |
| Floquet, A | 1 |
| Marsault, C | 1 |
| Quétin, P | 1 |
| Pujol, J | 1 |
| Maton, O | 1 |
| Dujols, JP | 1 |
| Caudry, Y | 1 |
| Skawinski, P | 1 |
| Tono, T | 2 |
| Tamaki, Y | 1 |
| Yagyu, T | 1 |
| Mishima, H | 1 |
| Nakagawa, H | 1 |
| Cho, G | 1 |
| Shin, E | 1 |
| Kobayashi, K | 1 |
| Takatsuka, Y | 1 |
| Kikkawa, N | 2 |
| Nakamori, S | 1 |
| Imaoka, S | 2 |
| Yasuda, T | 3 |
| Nakano, H | 2 |
| Hiratsuka, M | 2 |
| Sasaki, Y | 2 |
| Kabuto, T | 2 |
| Takano, S | 2 |
| Moriguchi, M | 1 |
| Seki, N | 2 |
| Higaki, T | 1 |
| Watanabe, Y | 1 |
| Takahashi, T | 8 |
| Ito, Y | 1 |
| Oishi, H | 1 |
| Nakata, Y | 1 |
| Kono, S | 1 |
| Tomita, F | 2 |
| Kurosaka, Y | 2 |
| Matsushita, M | 2 |
| Kiriyama, M | 1 |
| Kosaka, T | 1 |
| Kita, I | 1 |
| Takashima, S | 2 |
| Bradley, C | 1 |
| Selby, P | 1 |
| Arisawa, Y | 3 |
| Sutanto-Ward, E | 2 |
| Dalton, RR | 1 |
| Sigurdson, ER | 2 |
| Kawahara, H | 1 |
| Hirai, K | 1 |
| Ashikaga, K | 1 |
| Kimura, C | 1 |
| Kuroda, H | 1 |
| Ono, M | 1 |
| Aoki, T | 3 |
| Okuno, K | 5 |
| Ohnishi, H | 1 |
| Nakajima, I | 1 |
| Akabane, Y | 1 |
| Kurooka, K | 2 |
| Koh, K | 2 |
| Shindo, K | 3 |
| Yasutomi, M | 7 |
| Egeli, R | 3 |
| Arma, S | 3 |
| Barras, JP | 1 |
| Martinoli, S | 3 |
| Müller, W | 3 |
| Castiglione, M | 1 |
| Schroeder, R | 1 |
| Yamaguchi, A | 4 |
| Maeda, A | 1 |
| Hachisuka, K | 1 |
| Yura, J | 1 |
| Honda, K | 1 |
| Honda, H | 1 |
| Yoshizaki, S | 1 |
| Tsuruga, N | 1 |
| Nakazato, H | 1 |
| Mattioli, R | 1 |
| Silva, RR | 1 |
| Battelli, N | 1 |
| Manocchi, P | 1 |
| Pilone, A | 1 |
| Rossini, S | 1 |
| Delprete, S | 1 |
| Mazzanti, P | 1 |
| Bascioni, R | 1 |
| Battelli, T | 1 |
| Yamaguchi, T | 3 |
| Hagiwara, A | 1 |
| de Takats, PG | 1 |
| Kerr, DJ | 3 |
| Poole, CJ | 1 |
| Warren, HW | 1 |
| McArdle, CS | 2 |
| Poplin, EA | 1 |
| LoRusso, P | 1 |
| Lokich, JJ | 1 |
| Gullo, JJ | 1 |
| Leming, PD | 1 |
| Schulz, JJ | 1 |
| Veach, SR | 1 |
| McCulloch, W | 1 |
| Baker, L | 1 |
| Schein, P | 1 |
| Shiiba, K | 1 |
| Ouchi, A | 1 |
| Yamamoto, K | 2 |
| Kunii, Y | 1 |
| Yamazaki, T | 1 |
| Momono, S | 1 |
| Nakagawa, K | 3 |
| Muto, I | 1 |
| Mashiko, H | 1 |
| Wada, M | 1 |
| Akaike, M | 1 |
| Takemiya, S | 1 |
| Sugimasa, Y | 1 |
| Okamoto, T | 1 |
| Mäkelä, J | 2 |
| Tikkakoski, T | 2 |
| Leinonen, A | 1 |
| Siniluoto, T | 2 |
| Karttunen, A | 1 |
| Kairaluoma, MI | 1 |
| Endo, Y | 1 |
| Kawaguchi, A | 1 |
| Eguchi, Y | 1 |
| Sano, H | 1 |
| Kurumi, Y | 1 |
| Hanasawa, K | 1 |
| Terata, N | 1 |
| Shibata, J | 1 |
| Kitamura, K | 2 |
| Noguchi, A | 2 |
| Honda, M | 2 |
| Otsuji, E | 2 |
| Ohtsuka, K | 1 |
| Ono, K | 1 |
| Brockmann, WP | 1 |
| Wiegel, T | 1 |
| Sommer, K | 1 |
| Steiner, P | 1 |
| Hübener, KH | 1 |
| Nishimura, G | 1 |
| Michiwa, Y | 1 |
| Yagi, H | 1 |
| Sato, T | 2 |
| Fushida, S | 2 |
| Fugimura, T | 1 |
| Sugiyama, K | 1 |
| Kanno, M | 2 |
| Miwa, K | 2 |
| Miyazaki, I | 2 |
| Dirix, L | 1 |
| Catimel, G | 1 |
| Verdonk, R | 1 |
| De Bruijn, E | 1 |
| Tranchand, B | 1 |
| Ardiet, C | 1 |
| Van Oosterom, A | 1 |
| Miura, K | 1 |
| Koike, A | 1 |
| Takagi, H | 2 |
| Seymour, LW | 1 |
| Soyez, H | 1 |
| De Marre, A | 1 |
| Shoaibi, MA | 1 |
| Schacht, EH | 1 |
| Tremiterra, S | 1 |
| Schneebaum, S | 2 |
| Arnold, MW | 2 |
| Staubus, A | 1 |
| Young, DC | 1 |
| Dumond, D | 1 |
| Martin, EW | 2 |
| Kubo, R | 2 |
| Ikeda, E | 1 |
| Teramoto, T | 2 |
| Okuda, M | 1 |
| Yamamoto, Y | 1 |
| Isomoto, H | 2 |
| Koslowe, P | 1 |
| Staubus, AE | 1 |
| Rump, AF | 2 |
| Botvinik-Helling, S | 2 |
| Theisohn, M | 2 |
| Biederbick, W | 2 |
| Schierholz, JM | 1 |
| Stemmler, M | 1 |
| Fischbach, R | 2 |
| Heindel, W | 2 |
| Lackner, K | 2 |
| Klaus, W | 2 |
| Fujii, M | 2 |
| Yamaue, H | 1 |
| Tanimura, H | 1 |
| Nakamori, M | 1 |
| Noguchi, K | 1 |
| Iwahashi, M | 1 |
| Tani, M | 1 |
| Hotta, T | 1 |
| Murakami, K | 1 |
| Ishimoto, K | 1 |
| Marinelli, A | 2 |
| de Brauw, LM | 1 |
| Beerman, H | 1 |
| Keizer, HJ | 1 |
| van Bockel, JH | 1 |
| Tjaden, UR | 1 |
| van de Velde, CJ | 2 |
| Rafique, M | 1 |
| Adachi, W | 2 |
| Koike, S | 1 |
| Kajikawa, S | 2 |
| Yazawa, K | 1 |
| Sugenoya, A | 1 |
| Amano, J | 1 |
| Joseph, G | 1 |
| Bäcker, A | 1 |
| Woschee, U | 1 |
| Nonami, T | 1 |
| Takeuchi, Y | 1 |
| Yasui, M | 1 |
| Kurokawa, T | 1 |
| Taniguch, K | 1 |
| Harada, A | 1 |
| Nakao, A | 1 |
| Kantola, R | 1 |
| Leinonen, S | 1 |
| Kiviniemi, H | 1 |
| Laitinen, S | 1 |
| Kairaluoma, M | 1 |
| Aitini, E | 1 |
| Rabbi, C | 1 |
| Cavazzini, G | 1 |
| Bertani, M | 1 |
| Pulica, C | 1 |
| Campo, S | 1 |
| Pari, F | 1 |
| Mambrini, A | 1 |
| Bezzi, A | 1 |
| Zamagni, D | 1 |
| Amadori, M | 1 |
| Smerieri, F | 1 |
| Masutani, S | 1 |
| Tatsuta, M | 1 |
| Kawasaki, T | 1 |
| Morimoto, O | 1 |
| Tsuji, Y | 2 |
| Shiozaki, K | 1 |
| Baba, S | 1 |
| Miya, A | 1 |
| Satomi, T | 1 |
| Minamimura, T | 1 |
| Katsuyama, S | 1 |
| Yamasaki, K | 1 |
| Ookami, H | 1 |
| Okamoto, M | 1 |
| Masuyama, K | 1 |
| Takemori, S | 1 |
| Arai, H | 1 |
| Sakamoto, T | 1 |
| Tazawa, K | 1 |
| Fujimaki, M | 1 |
| Akasu, T | 1 |
| Moriya, Y | 5 |
| Takayama, T | 1 |
| Kawabata, K | 1 |
| Nio, Y | 2 |
| Imamura, M | 1 |
| Hartmann, JT | 1 |
| Harstrick, A | 1 |
| Daikeler, T | 1 |
| Kollmannsberger, C | 1 |
| Müller, C | 1 |
| Seeber, S | 2 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Giovannini, M | 1 |
| Capodano, G | 1 |
| Bernardini, D | 1 |
| Bardou, VJ | 1 |
| Vahrmeijer, AL | 1 |
| Tsugawa, T | 1 |
| Furukawa, H | 1 |
| Kasperk, R | 1 |
| Hosoya, Y | 1 |
| Konishi, H | 1 |
| Horie, H | 1 |
| Ishizuka, T | 1 |
| Shitou, K | 1 |
| Kojima, M | 1 |
| Kashiwagi, H | 1 |
| Furukawa, T | 1 |
| Kubota, T | 1 |
| Hoffman, RM | 1 |
| Stewart, JM | 1 |
| Millward, MJ | 1 |
| Kokudo, N | 1 |
| Seki, M | 1 |
| Azekura, K | 1 |
| Ueno, M | 1 |
| Moroguchi, A | 1 |
| Matsubara, T | 1 |
| Nakajima, T | 2 |
| Aiba, K | 1 |
| Ducreux, M | 2 |
| Gil-Delgado, M | 1 |
| André, T | 1 |
| Ychou, M | 1 |
| de Gramond, A | 1 |
| Khayat, D | 1 |
| Kornmann, M | 3 |
| Leder, G | 2 |
| Pillasch, AF | 1 |
| Sunelaitis, E | 2 |
| Schatz, M | 2 |
| Pressmar, J | 1 |
| Beger, HG | 3 |
| Takeda, A | 2 |
| Nakajima, K | 2 |
| Shimada, H | 3 |
| Imaseki, H | 2 |
| Takayama, W | 2 |
| Hayashi, H | 1 |
| Suzuki, T | 2 |
| Ochiai, T | 3 |
| Isono, K | 2 |
| Kaneda, K | 1 |
| Rudroff, C | 1 |
| Altendorf-Hoffmann, A | 1 |
| Stangl, R | 2 |
| Scheele, J | 2 |
| Ambiru, S | 1 |
| Miyazaki, M | 1 |
| Shimizu, H | 1 |
| Nakajima, N | 1 |
| Leichman, CG | 1 |
| Jacobson, JR | 1 |
| Modiano, M | 1 |
| Daniels, JR | 1 |
| Zalupski, MM | 1 |
| Doroshow, JH | 1 |
| Fletcher, WS | 1 |
| Macdonald, JS | 1 |
| van der Vange, N | 1 |
| Kaag, MM | 2 |
| Ukei, T | 1 |
| Touno, T | 1 |
| Oozato, H | 1 |
| Yamamoto, H | 1 |
| Fukuda, K | 1 |
| Takanishi, K | 1 |
| Matsumoto, J | 1 |
| Minami, T | 1 |
| Anderson, N | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Chester, JD | 1 |
| Dent, JT | 1 |
| Wilson, G | 1 |
| Ride, E | 1 |
| Seymour, MT | 1 |
| Leder, GH | 1 |
| Pillasch, J | 2 |
| Danenberg, PV | 1 |
| Kamoshita, N | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Ohya, T | 2 |
| Nagaoka, H | 1 |
| Okabe, T | 1 |
| Kato, Y | 1 |
| Takeyoshi, I | 1 |
| Ohwada, S | 1 |
| Morishita, Y | 1 |
| Propper, DJ | 1 |
| Levitt, NC | 1 |
| O'Byrne, K | 1 |
| Braybrooke, JP | 1 |
| Talbot, DC | 1 |
| Ganesan, TS | 1 |
| Thompson, CH | 1 |
| Rajagopalan, B | 1 |
| Littlewood, TJ | 1 |
| Dixon, RM | 1 |
| Harris, AL | 1 |
| Botti, C | 1 |
| Cosimelli, M | 1 |
| Tedesco, M | 1 |
| Principi, F | 1 |
| Laurenzi, L | 1 |
| Cavaliere, R | 1 |
| Hinoshita, E | 1 |
| Uchiumi, T | 1 |
| Taguchi, K | 1 |
| Kinukawa, N | 1 |
| Tsuneyoshi, M | 1 |
| Sugimachi, K | 4 |
| Kuwano, M | 1 |
| Pizzutilli, A | 1 |
| Mancini, E | 1 |
| Varrone, A | 1 |
| Palumbo, G | 1 |
| Amicucci, G | 1 |
| Perri, S | 1 |
| Okazumi, S | 1 |
| Iwasaki, K | 1 |
| Makino, H | 1 |
| Natsume, T | 1 |
| Kouno, T | 1 |
| Kondo, S | 1 |
| Baba, H | 1 |
| Endo, K | 1 |
| Ikeda, Y | 1 |
| Toh, Y | 1 |
| Nakashima, H | 1 |
| Okamura, T | 1 |
| Focan, C | 1 |
| Bury, J | 1 |
| Beauduin, M | 1 |
| Herman, ML | 1 |
| Vindevoghel, A | 1 |
| Brohée, D | 1 |
| Lecomte, M | 1 |
| Tassinari, D | 1 |
| Arcangeli, V | 1 |
| Panzini, I | 1 |
| Sartori, S | 1 |
| Gianni, L | 1 |
| Ravaioli, A | 2 |
| Hejna, M | 1 |
| Köstler, WJ | 1 |
| Raderer, M | 2 |
| Tomek, S | 1 |
| Brodowicz, T | 1 |
| Scheithauer, W | 2 |
| Wiltschke, C | 1 |
| Zielinski, CC | 1 |
| Takahashi, H | 1 |
| Nakano, Y | 1 |
| Ohzato, H | 1 |
| Fukunaga, M | 1 |
| Watanabe, H | 1 |
| Kanoh, Y | 1 |
| Yasue, A | 1 |
| Okada, K | 1 |
| Hata, T | 1 |
| Iwazawa, T | 1 |
| Matsui, S | 1 |
| Yano, H | 1 |
| Kinuta, M | 1 |
| Okamura, J | 1 |
| Monden, T | 1 |
| Oosawa, T | 1 |
| Sakimoto, T | 1 |
| Waters, J | 1 |
| Shatari, T | 1 |
| Nozawa, K | 1 |
| Comella, P | 1 |
| Biglietto, M | 1 |
| Casaretti, R | 1 |
| De Lucia, L | 1 |
| Avallone, A | 1 |
| Maiorino, L | 1 |
| Di Lullo, L | 1 |
| De Cataldis, G | 1 |
| Rivellini, F | 1 |
| Comella, G | 1 |
| Sobrero, A | 1 |
| Guglielmi, A | 1 |
| Cirillo, M | 1 |
| Recaldin, E | 1 |
| Frassineti, GL | 1 |
| Aschele, C | 1 |
| Testore, P | 1 |
| Caroti, C | 1 |
| Gallo, L | 1 |
| Pessi, MA | 1 |
| Turci, D | 1 |
| Grossi, F | 1 |
| Labianca, R | 1 |
| de Bree, E | 1 |
| van Slooten, GW | 1 |
| van Coevorden, F | 1 |
| Grumett, SA | 1 |
| Archer, VR | 1 |
| Midgley, R | 1 |
| Mulholland, P | 1 |
| Nicum, S | 1 |
| Blewitt, L | 1 |
| Blot, F | 1 |
| El Otmany, A | 1 |
| Antoun, S | 1 |
| Lasser, P | 1 |
| Boige, V | 1 |
| Rougier, P | 2 |
| Hishikawa, Y | 1 |
| Kohno, H | 1 |
| Ueda, S | 1 |
| Kimoto, T | 1 |
| Dhar, DK | 1 |
| Kubota, H | 1 |
| Tachibana, M | 1 |
| Koji, T | 1 |
| Nagasue, N | 1 |
| Ike, H | 1 |
| Sadahiro, S | 1 |
| Oya, K | 1 |
| Yamaguchi, S | 3 |
| Fujita, H | 1 |
| Mitomi, T | 3 |
| Hashimoto, Y | 1 |
| Ueda, K | 1 |
| Minami, K | 1 |
| Watatani, M | 1 |
| Nozu, S | 1 |
| Saitou, AY | 1 |
| Okayasu, K | 1 |
| Majima, T | 1 |
| Yagi, A | 1 |
| Murata, N | 1 |
| Gansauge, F | 1 |
| Formentini, A | 1 |
| Staib, L | 1 |
| Munemoto, Y | 1 |
| Iida, Y | 1 |
| Abe, J | 1 |
| Saito, H | 1 |
| Fujisawa, K | 1 |
| Kasahara, Y | 1 |
| Mitsui, T | 1 |
| Asada, Y | 1 |
| Miura, S | 1 |
| Deng, YC | 1 |
| Zhen, YS | 1 |
| Zheng, S | 1 |
| Xue, YC | 1 |
| Manziuk, LV | 1 |
| Artamonova, EV | 1 |
| Sholokhov, VN | 1 |
| Strygina, EA | 1 |
| Kiss, I | 1 |
| Marková, J | 1 |
| Tomásek, J | 1 |
| Vyzula, R | 1 |
| Válek, V | 1 |
| Boudný, J | 1 |
| Kala, Z | 1 |
| Hanke, I | 1 |
| Ostrízek, T | 1 |
| Leypold, J | 1 |
| Kornek, GV | 1 |
| Brugger, S | 1 |
| Ullrich-Pur, H | 1 |
| Valencak, J | 1 |
| Fiebiger, W | 1 |
| Kovats, E | 1 |
| Lang, F | 1 |
| Depisch, D | 1 |
| Popov, I | 1 |
| Lavrnić, S | 1 |
| Jelić, S | 1 |
| Jezdić, S | 1 |
| Jasović, A | 1 |
| Schilling, A | 1 |
| Gewiese, B | 1 |
| Berger, G | 1 |
| Boese-Landgraf, J | 1 |
| Fobbe, F | 1 |
| Stiller, D | 1 |
| Gallkowski, U | 1 |
| Wolf, KJ | 1 |
| Nakazaki, H | 2 |
| Kuramoto, S | 1 |
| Watanabe, M | 1 |
| Maeda, T | 1 |
| Hanawa, S | 1 |
| Hasebe, Y | 1 |
| Suzuki, Y | 1 |
| Yanagita, K | 1 |
| Yoshio, T | 1 |
| Tsukioka, Y | 1 |
| Ismail Ali, A | 1 |
| Simadibrata, R | 1 |
| Aziz Rani, A | 1 |
| Chudahman, M | 1 |
| Dharmika, D | 1 |
| Okuyama, K | 1 |
| Awano, T | 1 |
| Tohnosu, N | 1 |
| Koide, Y | 1 |
| Matsubara, H | 1 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Matsushita, K | 1 |
| Amano, H | 1 |
| O'Connell, MJ | 1 |
| Bécouarn, Y | 1 |
| Brunet, R | 1 |
| Ravaud, A | 1 |
| Bussières, E | 1 |
| Lagarde, P | 1 |
| Tsavaris, N | 1 |
| Tzannou, I | 1 |
| Karvounis, N | 1 |
| Kosmidis, P | 1 |
| Arigoni, M | 1 |
| Barras, J | 2 |
| Schweizer, W | 2 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| Bellmunt, J | 1 |
| Albanell, J | 1 |
| Gallego, OS | 1 |
| Vicente, P | 1 |
| Tsuchiya, S | 3 |
| Iijima, N | 2 |
| Aso, K | 2 |
| Suzuki, K | 2 |
| Nishiyama, K | 2 |
| Amano, T | 2 |
| Murayama, N | 2 |
| Oka, H | 3 |
| Barone, C | 2 |
| Ricevuto, E | 1 |
| Cassano, A | 1 |
| Astone, A | 1 |
| Pozzo, C | 1 |
| Sofo, L | 1 |
| Netri, G | 1 |
| Ratto, C | 1 |
| Coco, C | 1 |
| Codacci-Pisanelli, G | 1 |
| Codacci-Pisanelli, M | 1 |
| Ferri, GM | 1 |
| Garufi, C | 1 |
| Grieco, A | 1 |
| Pagani, V | 1 |
| Konovalova, N | 1 |
| Altendorf-Hofmann, A | 1 |
| Gall, FP | 1 |
| Tsekova, V | 1 |
| Koĭnov, K | 1 |
| Velikova, M | 1 |
| Goldberg, JA | 1 |
| Blackie, R | 1 |
| Whately, TL | 1 |
| Pettit, L | 1 |
| Tomita, M | 2 |
| Shimoyama, T | 1 |
| Hirano, T | 2 |
| Nakagoe, T | 2 |
| Kusano, H | 1 |
| Eida, K | 2 |
| Ishii, T | 2 |
| Kotake, Y | 2 |
| Matsuda, T | 2 |
| Kikuchi, K | 1 |
| Kasai, Y | 1 |
| Abe, O | 2 |
| Kondo, T | 1 |
| Taguchi, T | 1 |
| Hattori, T | 1 |
| Inokuchi, K | 1 |
| Komi, N | 1 |
| Itani, K | 2 |
| Yoshikawa, T | 2 |
| Oyamada, H | 2 |
| Ichikawa, H | 2 |
| Kokura, S | 1 |
| Tainaka, K | 2 |
| Sugino, S | 2 |
| Weder, W | 1 |
| Röthlin, M | 1 |
| Largiadèr, F | 1 |
| Kusumoto, T | 2 |
| Sakaguchi, Y | 2 |
| Emi, Y | 1 |
| Ishida, Y | 1 |
| Kusumoto, S | 1 |
| Nakayoshi, A | 1 |
| Takegawa, S | 1 |
| Kumaki, T | 1 |
| Katoh, M | 1 |
| Gotohda, H | 1 |
| Saitoh, H | 1 |
| Kinami, Y | 1 |
| Kurosawa, H | 1 |
| Ohki, S | 2 |
| Joh, T | 2 |
| Imai, S | 3 |
| Matsuo, K | 2 |
| Fukano, M | 2 |
| Hasegawa, S | 1 |
| Tokitoh, T | 1 |
| Masui, H | 1 |
| Sugihara, K | 2 |
| Hojo, K | 4 |
| Makuuchi, M | 1 |
| Tsujitani, S | 1 |
| Watanabe, A | 1 |
| Tomoda, H | 1 |
| Furusawa, M | 1 |
| Tobinaga, K | 1 |
| Nogawa, T | 1 |
| Furue, H | 1 |
| Shiraishi, T | 1 |
| Tsubono, M | 1 |
| Morimoto, H | 1 |
| Tseng, CC | 1 |
| Tobe, T | 1 |
| Yasui, K | 1 |
| Berres, M | 1 |
| Jäggi, P | 1 |
| Nishimura, A | 1 |
| Katsuki, Y | 1 |
| Yasuda, D | 1 |
| Kimura, K | 1 |
| Koyanagi, Y | 1 |
| Kakuta, T | 2 |
| Sakurai, H | 1 |
| Tsuchida, A | 1 |
| Yoshimatsu, A | 1 |
| Ozawa, H | 1 |
| Fukunaga, J | 1 |
| Kitahama, H | 1 |
| Okuyama, A | 1 |
| Seki, T | 1 |
| Tsurui, K | 1 |
| Saka, M | 1 |
| Sasagawa, M | 1 |
| Hishinuma, S | 1 |
| Yasuda, S | 1 |
| Noto, T | 1 |
| Mukai, M | 1 |
| Mizutani, K | 1 |
| Gotoh, K | 1 |
| Tsukui, M | 1 |
| Ohtani, Y | 1 |
| Tanaka, Y | 1 |
| Kawano, N | 1 |
| Houjo, K | 1 |
| Iijima, K | 1 |
| Nakajima, S | 1 |
| Hamahata, Y | 1 |
| Tsuchiya, Y | 1 |
| Kawahara, T | 1 |
| Schultheis, KH | 1 |
| Gebhardt, C | 1 |
| Schwemmle, K | 1 |
| Richter, EI | 1 |
| Schumacher, F | 1 |
| Safi, F | 1 |
| Schumacher, K | 1 |
| Roscher, R | 1 |
| Bittner, R | 1 |
| Herait, P | 1 |
| Theodore, C | 1 |
| Kac, JL | 1 |
| Droz, JP | 1 |
| Henne-Bruns, D | 1 |
| Marks, HG | 1 |
| Marks, V | 1 |
| Weh, HJ | 1 |
| Kremer, B | 1 |
| Klapdor, R | 1 |
| Franke, N | 1 |
| Bahlo, M | 1 |
| Teshima, Y | 1 |
| Yamagata, M | 1 |
| Tanaka, T | 1 |
| Sakabe, T | 1 |
| Fujiyoshi, M | 1 |
| Shirouzu, K | 1 |
| Ogata, Y | 1 |
| Kimitsuki, H | 1 |
| Hiraki, M | 1 |
| Kakegawa, T | 1 |
| Takano, H | 1 |
| Maruyama, J | 1 |
| Morikawa, E | 1 |
| Hida, J | 1 |
| Ko, K | 1 |
| Inoue, Y | 1 |
| Ishiguro, M | 1 |
| Wakatsuki, T | 1 |
| Hamazoe, R | 1 |
| Shimizu, N | 1 |
| Maeta, M | 1 |
| Koga, S | 1 |
| Saku, M | 1 |
| Bär, HU | 1 |
| Schneider, A | 1 |
| Kemeny, N | 1 |
| Chapman, D | 1 |
| Niedzwiecki, D | 1 |
| Oderman, P | 1 |
| Horigome, N | 1 |
| Hanasaki, K | 1 |
| Kinosita, T | 1 |
| Sodeyama, H | 1 |
| Kuroda, T | 1 |
| Iida, F | 1 |
| Ishikawa, T | 1 |
| Eguchi, H | 1 |
| Mitsugi, O | 1 |
| Iimura, Y | 1 |
| Sugahara, K | 1 |
| Hottenrott, C | 1 |
| Akamatsu, H | 1 |
| Takabayashi, T | 1 |
| Nakayama, T | 1 |
| Ficorella, C | 1 |
| Cagnazzo, P | 1 |
| Cardi, G | 1 |
| Ricciuti, FP | 1 |
| Marchetti, P | 1 |
| Frati, L | 1 |
| Marchei, P | 1 |
| Migeod, F | 1 |
| Gerlach, D | 1 |
| Kress, M | 1 |
| Hoffmann, W | 1 |
| Farroukh, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C[NCT05513183] | 74 participants (Actual) | Observational | 2021-05-20 | Completed | |||
| Comparative Study on the Efficacy of Mitomycin and Lobaplatin in the Treatment of Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04845490] | Phase 2 | 201 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies[NCT04729205] | Phase 1 | 9 participants (Actual) | Interventional | 2021-01-13 | Terminated (stopped due to Investigational drug not available) | ||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma[NCT02614534] | Phase 3 | 200 participants (Anticipated) | Interventional | 2015-11-16 | Active, not recruiting | ||
| The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer[NCT00294359] | Phase 2/Phase 3 | 333 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| An Open-label, Phase 1b Study of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Advanced Cancer Requiring Palliative Radiotherapy[NCT03823989] | Phase 1 | 18 participants (Actual) | Interventional | 2019-01-03 | Completed | ||
| Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial[NCT00454519] | Phase 2 | 60 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | ||
| Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Recurrence in Patients With High-risk Colorectal and Appendiceal Neoplasms : a Pilot Study[NCT05623787] | 30 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | |||
| Thrombin Generation and Platelet Activation in Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT03034850] | 27 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy[NCT02741167] | 90 participants (Anticipated) | Observational | 2016-01-31 | Recruiting | |||
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma[NCT00226473] | Phase 4 | 200 participants | Interventional | 2001-09-30 | Recruiting | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
35 reviews available for mitomycin and Colorectal Cancer
| Article | Year |
|---|---|
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review.
Topics: Adult; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction S | 2022 |
After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Proce | 2019 |
Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Proce | 2020 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boro | 2003 |
Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer: a systematic review and evidence synthesis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2016 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2008 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Is there a role for mitomycin C in metastatic colorectal cancer?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neopla | 2010 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
[Review of comparative studies of postoperative adjuvant chemotherapy after curatively resected colorectal cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2002 |
[Progress in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2002 |
[The role of the regional (intra-arterial) chemotherapy in the treatment of hepatic metastases of colorectal cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing | 2003 |
[Hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Ad | 2004 |
[Targeting therapy of gastric and colorectal cancer].
Topics: Colorectal Neoplasms; Drug Delivery Systems; Fat Emulsions, Intravenous; Fluorouracil; Humans; Infus | 1994 |
Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1994 |
[Diagnosis and therapy for metastatic liver cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Colorectal Neoplasms; Co | 1996 |
Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 1996 |
Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1997 |
Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topi | 1998 |
[Multidisciplinary treatment for colorectal liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1999 |
Regional IL-2-based immunochemotherapy of colorectal liver metastases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II a | 2000 |
Combination chemotherapy and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2000 |
The changing face of chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; | 2001 |
[Recent advances is surgical adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2000 |
[Multidisciplinary treatment for liver metastasis using cytokines].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2001 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
[Systemic chemotherapy in metastatic colorectal adenocarcinomas].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem | 1992 |
111 trials available for mitomycin and Colorectal Cancer
| Article | Year |
|---|---|
Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Drug Resistance, N | 2020 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap | 2021 |
MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disea | 2018 |
HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; H | 2018 |
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2018 |
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduc | 2021 |
Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Chemoembolization, Therapeutic; Colorect | 2013 |
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2013 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Reg | 2013 |
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2014 |
Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neo | 2014 |
Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; D | 2014 |
Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Cancer, Regional Perf | 2015 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; China; Cisplatin; | 2014 |
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2015 |
Radiofrequency Ablation Combined with Hepatic Arterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Liver Metastasis from Colorectal Cancer: A Prospective Multicenter Study.
Topics: Aged; Aged, 80 and over; Catheter Ablation; Chemoembolization, Therapeutic; Colorectal Neoplasms; Co | 2017 |
Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2008 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2009 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
Phase II study of regional treatment for peritoneal carcinomatosis.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chemotherapy, Cancer, R | 2009 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2011 |
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Cancer, Regional Perfus | 2012 |
Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2012 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
[Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 2002 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Squar | 2003 |
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Circadian Rhythm; Colorectal Neoplasms; Fluorouracil; Humans; | 2004 |
Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2004 |
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional | 2004 |
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Epirubicin; Filtration; Humans | 2004 |
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2005 |
Long-term survival of peritoneal carcinomatosis of colorectal origin.
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fol | 2005 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2005 |
Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 2006 |
Sitilo experience on peritoneal carcinomatosis from colorectal cancer: clinical prognostic features.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Colorectal Neoplasms; Combined Mod | 2003 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2006 |
The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2006 |
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Parente | 2007 |
Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2007 |
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.
Topics: Adult; Aged; Antineoplastic Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil D | 2007 |
Staged laparoscopic adjuvant intraperitoneal chemohyperthermia after complete resection for locally advanced colorectal or gastric cancer: a preliminary experience.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modali | 2009 |
[Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1995 |
[The study of chemotherapy via the reservoir to colo-rectal cancer patients with liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
[Effect of prophylactic intra-arterial infusion of anticancer drugs on post hepatic resection for hepatic metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1994 |
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1995 |
[Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Do | 1994 |
[Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1994 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1994 |
[Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
[Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; | 1994 |
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Amifostine; Bone Marrow Diseases; Colorectal Neoplasms; Female; Humans; Male; Middle Ag | 1994 |
[A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Epir | 1993 |
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
[Evaluation of preoperative chemotherapy for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1996 |
Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drugs, Inv | 1995 |
Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1996 |
[Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 1996 |
Pharmacokinetics of intraarterial mitomycin C in the chemoembolisation treatment of liver metastases.
Topics: Antibiotics, Antineoplastic; Area Under Curve; Chemoembolization, Therapeutic; Colorectal Neoplasms; | 1996 |
Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neopl | 1996 |
Disposition of mitomycin C after local intraarterial application.
Topics: Antibiotics, Antineoplastic; Biological Availability; Chemoembolization, Therapeutic; Colorectal Neo | 1997 |
Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Colorectal Neoplasms; Female; Follow-Up | 1997 |
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio | 1998 |
5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1998 |
Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1999 |
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplat | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2000 |
[The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ | 2000 |
Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.
Topics: Adult; Aged; Benzaldehydes; Cell Hypoxia; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combin | 2000 |
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2000 |
Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer?
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2000 |
[Evaluation of hepatic resection following hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 2000 |
UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Therapy, Com | 2000 |
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antin | 2001 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne | 2001 |
[Combination chemotherapy of doxifluridine plus mitomycin C for colorectal lung metastasis--phase II study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2001 |
Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Col | 2002 |
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit.
Topics: Aged; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free | 2002 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
[Final evaluation of the randomized multicenter study SAKK 40/81: adjuvant portal chemotherapy of curatively resected colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1992 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemothera | 1992 |
5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug E | 1991 |
[Multihospital randomized study on pre- and post-operative adjuvant chemotherapy for colorectal cancer (Part 2)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1991 |
[Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five-year results. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dox | 1991 |
Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1991 |
[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Colorectal Neoplasms; Combined Mo | 1990 |
[Chemoembolization of colorectal liver metastases].
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diatrizoate; Drug Combinations; Emboli | 1990 |
[Intra-portal chemoprevention and therapy of liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Comb | 1989 |
[Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma. (Second report): 5-year survival rate. Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1989 |
[Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum].
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1989 |
[Effects of prophylactic intraportal chemotherapy on liver function, blood profile and survival in patients with colo-rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 1989 |
[Initial results of adjuvant portal liver infusion following radical surgery of colorectal cancer (Swiss Study Group for Epidemiologic and Clinical Cancer Research Study 40/81)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1989 |
[European topic: liver surgery II--regional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 1989 |
224 other studies available for mitomycin and Colorectal Cancer
| Article | Year |
|---|---|
Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2022 |
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
Topics: Adult; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermic Intrape | 2022 |
A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Basic-Leucine Zipper Transcription Factors; Cell Lin | 2022 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
PD-1 Blockade Combined with Heated Intraperitoneal Chemotherapy Improves Outcome in Experimental Peritoneal Metastases from Colonic Origin in a Murine Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality The | 2023 |
Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin α1.
Topics: Animals; Colorectal Neoplasms; Combined Modality Therapy; Hyperthermia, Induced; Mice; Mitomycin; Ne | 2023 |
Mitomycin C enhanced the antitumor efficacy of Rocaglamide in colorectal cancer.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms | 2023 |
Open versus Closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): Morbidity and Mortality outcomes from a high-volume centre.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Treating colorectal peritoneal metastases with an injectable cytostatic loaded supramolecular hydrogel in a rodent animal model.
Topics: Animals; Colonic Neoplasms; Colorectal Neoplasms; Cytostatic Agents; Hydrogels; Mitomycin; Peritonea | 2023 |
2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Con | 2024 |
Beware mis-representation of PRODIGE 7: danger of throwing out the cytoreductive surgery baby with the hyperthermic intraperitoneal chemotherapy bathwater.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Australia; Carcinoma, Ovarian Epithelia | 2019 |
Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neop | 2020 |
Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Chemot | 2020 |
Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2020 |
Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Cytoreduction Surgical Procedure | 2020 |
Effect of intraperitoneal chemotherapy concentration on morbidity and survival.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Dat | 2020 |
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases.
Topics: Acute Kidney Injury; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2020 |
Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Colorectal Neoplasms; Cytored | 2020 |
Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Topics: Aged; Alleles; Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Cytochrome P-450 Enzyme | 2020 |
The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms | 2020 |
Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI).
Topics: Aged; Cisplatin; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; | 2021 |
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Colorectal Neoplasms; Drug | 2021 |
Intraperitoneal collagenase as a novel therapeutic approach in an experimental model of colorectal peritoneal carcinomatosis.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma; Collagenases; Colorectal Neoplasms; Disease Models, | 2021 |
Individual learning curve of cytoreductive surgery for peritoneal metastasis from colorectal cancer: A process with an impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cholecystectomy; Colectomy; | 2021 |
MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Cisplatin; Colorectal Neo | 2021 |
Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colorectal Neoplasms; Female; Humans; Hyp | 2021 |
10 ns PEFs induce a histological response linked to cell death and cytotoxic T-lymphocytes in an immunocompetent mouse model of peritoneal metastasis.
Topics: Animals; Antibiotics, Antineoplastic; Cell Death; Colorectal Neoplasms; Combined Modality Therapy; D | 2021 |
Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Colorectal Neoplasms; Combined Modal | 2021 |
Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction S | 2021 |
The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI).
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2021 |
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell | 2017 |
Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
Topics: Alleles; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms | 2017 |
5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; H | 2018 |
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Sur | 2018 |
Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cohort Studies; Colorectal Neoplasms; Combined Modality Ther | 2018 |
CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma; Cohort St | 2018 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Fem | 2018 |
Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
Topics: Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Su | 2018 |
Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Hyperthermia, | 2019 |
A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Co | 2013 |
The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis.
Topics: Animals; Carcinoma; Cell Line, Tumor; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Color | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Stu | 2014 |
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Blood Loss, Surgical; Chemotherapy, Ca | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusio | 2014 |
Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2014 |
Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2014 |
Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combin | 2014 |
Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Colorec | 2014 |
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Colore | 2014 |
[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Protocols; Appendiceal Neoplasms; Carcinoma; Chemotherap | 2014 |
Resveratrol enhances mitomycin C-mediated suppression of human colorectal cancer cell proliferation by up-regulation of p21WAF1/CIP1.
Topics: alpha Karyopherins; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell | 2014 |
Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms | 2015 |
Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Blood Loss, Surgical; Colorectal Neoplasms; Cytoreduction Surgical Proc | 2015 |
The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Colorectal Neoplas | 2015 |
Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2015 |
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Canc | 2016 |
Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Borte | 2015 |
Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; | 2016 |
MnTnBuOE-2-PyP protects normal colorectal fibroblasts from radiation damage and simultaneously enhances radio/chemotherapeutic killing of colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senesc | 2016 |
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduc | 2016 |
Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheter Ablation; Colo | 2016 |
Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Delaye | 2016 |
Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Topics: Adult; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Doxo | 2016 |
Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; | 2017 |
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neoplasms; Combined | 2016 |
The effects of hyperthermic intraperitoneal chemoperfusion on colonic anastomosis: an experimental study in a rat model.
Topics: Anastomosis, Surgical; Animals; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neoplasms; Combined Mo | 2017 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoe | 2009 |
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antit | 2009 |
Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, P | 2009 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2010 |
Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Topics: Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combine | 2010 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 2010 |
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; H | 2010 |
Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplatin; Colorecta | 2011 |
Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings.
Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Stud | 2011 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2010 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Diseases; Causality; Cohort Studies; Colorectal Neopla | 2012 |
A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined | 2012 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
N-3 PUFAs have antiproliferative and apoptotic effects on human colorectal cancer stem-like cells in vitro.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferat | 2013 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2002 |
[Audit of the safety of hepatic arterial infusion of degradable starch microspheres (DSM). Adriamycin (ADM).mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biodegradation, Environmental; Colorectal Neop | 2002 |
Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases.
Topics: Adult; Aged; Area Under Curve; Colorectal Neoplasms; Embolization, Therapeutic; Female; Humans; Hypo | 2002 |
[A case report of complete remission of liver metastases from colorectal cancer treated with continuous hepatic arterial infusion].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 2003 |
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2003 |
[Relationship between effectiveness of hepatic artery injection chemotherapy and serum VEGF].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Chemoembo | 2003 |
[Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2003 |
[Evaluation of liver metastasis of colorectal cancer following hepatic arterial infusion with degradable starch microspheres and adriamycin, mitomycin C as seen in changes in CEA at early stage of therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoe | 2003 |
[Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Cisplatin; Colorectal Neoplasms; | 2003 |
Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
Topics: Antibiotics, Antineoplastic; Area Under Curve; Bayes Theorem; Colorectal Neoplasms; Female; Humans; | 2004 |
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Disease-Fre | 2004 |
Widening eligibility to phase II trials: constant arcsine difference phase II trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2004 |
Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2004 |
[Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2004 |
[Efficacy of hepatic arterial infusion of adriamycin and mitomycin C mixed with degradable starch microspheres for liver metastasis of colorectal cancer--correlation with the mRNA expression of DNA topoisomerase-IIalpha and glutathione-S transferase-pi in
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[Histological examination of the effect of hepatic arterial infusion of degradable starch microspheres mixed with adriamycin and mitomycin C for liver metastases of colorectal cancer--second report].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biodegradation, Environmental; Colorect | 2004 |
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Color | 2004 |
C-MYB, serum P-53M, genetic instability, labeling index and endoscopic findings in patients with adenoma or colorectal cancer.
Topics: Adenoma; Biomarkers, Tumor; Chromosome Aberrations; Colorectal Neoplasms; Disease Progression; DNA; | 2004 |
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2005 |
Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, N | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Color | 2005 |
Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery.
Topics: Abdomen; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Arteries; Chemoembolization, | 2005 |
Science to practice: can combination therapy for colorectal liver metastases improve results over chemoembolization or ablation alone?
Topics: Animals; Antibiotics, Antineoplastic; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined | 2005 |
Liver metastases in rats: chemoembolization combined with interstitial laser ablation for treatment.
Topics: Analysis of Variance; Animals; Antibiotics, Antineoplastic; Chemoembolization, Therapeutic; Colorect | 2005 |
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin | 2005 |
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2006 |
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2006 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
[New treatment of peritoneal carcinomatosis from colorectal cancer. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Topics: Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy | 2007 |
Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2008 |
Construction of humanized carcinoembryonic antigen specific single chain variable fragment and mitomycin conjugate.
Topics: Antibiotics, Antineoplastic; Apoptosis; Carcinoembryonic Antigen; Cell Line, Tumor; Cell Proliferati | 2007 |
[Home therapy approach in cancer patients-chemotherapy (case 2-3)--intra-arterial infusion cancer chemotherapy for hepatic metastasis of colorectal cancer--case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic | 1994 |
[Surgical therapy of liver metastases. Therapeutic procedures, results and prognostic factors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chem | 1994 |
[Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 1994 |
Management of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration S | 1994 |
Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1994 |
Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1993 |
[Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal | 1993 |
Superselective intra-arterial chemotherapy with mitomycin C in hepatic neoplasms.
Topics: Aged; Carcinoma, Hepatocellular; Colorectal Neoplasms; Female; Gallbladder Neoplasms; Hepatic Artery | 1993 |
[Prevention of postoperative recurrence after hepatic resection for metastatic colorectal cancer by adjuvant locoregional chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Chemotherapy, | 1993 |
Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 1993 |
[Concentration of mitomycin C in portal blood and peripheral blood after intra venous, intraperitoneal or intrapelvic administration].
Topics: Colorectal Neoplasms; Drug Administration Routes; Humans; Infusions, Intravenous; Infusions, Parente | 1993 |
Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation.
Topics: Amino Acid Sequence; Animals; Antibiotics, Antineoplastic; Cell Survival; Colorectal Neoplasms; Dose | 1996 |
Regional chemotherapy for colorectal hepatic metastases: evidence for improved survival with new drug combinations.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 1996 |
Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases.
Topics: Antibiotics, Antineoplastic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Chemotherapy, Cancer, | 1996 |
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans | 1996 |
Peritoneal carcinomatosis and radioimmunoguided surgery.
Topics: Antibiotics, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Thera | 1996 |
Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Doxorubicin; Drug Screening Ass | 1996 |
Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Chemotherapy, Adjuvant; Colorect | 1997 |
Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Ad | 1997 |
[Combined intra-arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic | 1997 |
[Hepatic arterial chemotherapy for liver cancer over a period of 8 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Epirubicin; Female; | 1997 |
[Effects of OK-432 intraportal administration on cell-mediated immune responses].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Immunity, Cellular; Im | 1997 |
A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 1997 |
5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1997 |
5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Mitomyci | 1998 |
[Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Doxoru | 1998 |
5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Mitomyci | 1998 |
[Adjuvant regional arterial port chemotherapy after resection of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 1998 |
[Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 1998 |
Clinical applications of the histoculture drug response assay.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1995 |
Second line treatment options in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Multiple; Dru | 1998 |
Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1998 |
Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cispla | 1999 |
Adjuvant regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 1999 |
[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response R | 1999 |
[Intraarterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fe | 1999 |
[Management after hepatectomy of colorectal cancer metastases to the liver--intrahepatic arterial infusion chemotherapy and repeated hepatectomy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1999 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Treatment of peritoneal carcinomatosis with intent to cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neoplasms; Combined | 2000 |
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Topics: Adenocarcinoma; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; | 2000 |
Significance of duplex/colour Doppler sonography in hepatic arterial chemotherapy for patients with liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Flow Velocity; Case-Control Studies; Colorectal Neop | 2000 |
[Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
Topics: Antineoplastic Agents; Autoantibodies; Cisplatin; Colorectal Neoplasms; Drug Screening Assays, Antit | 2000 |
[Hepatic arterial injection of degradable starch microspheres (DSM) combined with adriamycin (ADM) and mitomycin C (MMC) in patients with liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxor | 2000 |
The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.
Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; | 2001 |
Expression of metallothionein in colorectal cancers and synchronous liver metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2001 |
The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins | 2001 |
[Clinical effectiveness of intra-arterial chemotherapy combined with degradable starch microspheres (DSM) for liver metastases and prediction of effectiveness by diagnostic imaging].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorectal Neoplasms | 2001 |
[Histological evaluation of liver metastasis of colorectal cancer following hepatic arterial infusion with degradable starch microspheres and adriamycin/mitomycin C].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Female; Hum | 2001 |
Activity of boanmycin against colorectal cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Colorectal Neoplas | 2001 |
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2001 |
[Personal experience with intra-arterial locoregional chemotherapy of liver metastases from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Doxorubicin; Female | 2001 |
Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouraci | 1992 |
[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1992 |
Chemotherapy for colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Colorectal Neopl | 1992 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fema | 1992 |
[Antineoplastic chemotherapy in digestive tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hum | 1991 |
5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA, Neoplasm; | 1991 |
Fractional incorporation of radionucleotides, a marker of in vitro tumor cell chemosensitivity in colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Daunorubicin; DNA, Neoplasm; Doxorubicin; Humans; In Vi | 1991 |
[Regional chemotherapy of diffuse liver metastases of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1991 |
[The adjuvant chemotherapy of patients with colorectal carcinoma (preliminary report)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adju | 1991 |
Mitomycin C-loaded microcapsules in the treatment of colorectal liver metastases. Pharmacokinetics of regionally administered particulate chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Compounding; Half-Life; Hepatic Artery; Humans; In | 1991 |
[Chemoembolization with degradable starch microspheres for liver metastases of colorectal cancer].
Topics: Carcinoembryonic Antigen; Colorectal Neoplasms; Embolization, Therapeutic; Humans; Liver Neoplasms; | 1991 |
Sarcoma-180 cells and human colorectal tumor cells under in vitro hypoxic conditions are more sensitive to mitomycin C and carboquone.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Carbazilquinone; Cell Hypoxia; Colorectal Neoplas | 1991 |
[Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colo | 1991 |
[Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Colorectal Neop | 1991 |
[Effects and complications of continuous hepatic arterial infusion chemotherapy using implantable reservoir for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Drug Administ | 1991 |
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1991 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
[The usefulness of UFT administration in colorectal cancer with emphasis on postoperative administration (Part 3)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1991 |
[Systemic chemotherapy of colorectal cancer--recent approaches].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T | 1991 |
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug | 1990 |
[Treatment of liver metastases from colorectal cancer--major hepatic resection and continuous hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hep | 1990 |
[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Colorectal Ne | 1990 |
[A study of low-dose intermittent intra-arterial infusion chemotherapy for liver metastasis in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1990 |
[Clinical evaluation and problem of intra-arterial infusion chemotherapy of liver metastasis from digestive organ cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl | 1990 |
[Hepatic arterial infusion chemotherapy using implantable reservoir in colorectal liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Doxorubicin; Fluoro | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
[Continuous hepatic arterial infusion chemotherapy using implantable reservoir in liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Drug | 1990 |
[Hepatic resection plus hepatic artery infusion with implantable port for colorectal metastases].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Hepatec | 1990 |
[Missile therapy of colorectal and pancreatic cancers--clinical trial of monoclonal antibody, A7-NCS, in 73 patients with colorectal and pancreatic cancers].
Topics: Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Colorectal Neoplasms; Doxorubicin; Drug A | 1990 |
Regional chemotherapy in liver metastases of colorectal carcinoma: monitoring with arterial computed tomography.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorub | 1990 |
Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1989 |
[Locoregional chemotherapy of liver tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1989 |
Combined therapy of xenografts of human pancreatic carcinomas with rTNF-alpha and mitomycin C.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Cell Division; Colorectal Neoplasms; Combined Mod | 1989 |
[Availability of intermittent chemotherapy by reservoir in liver metastasis of colo-rectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Evaluation Studie | 1989 |
[Intra-arterial infusion chemotherapy of liver metastases in colorectal cancer].
Topics: Adult; Aged; Catheterization; Colorectal Neoplasms; Female; Hepatic Artery; Humans; Infusion Pumps; | 1989 |
[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Combined Moda | 1989 |
[Chemoembolization with degradable starch microspheres for liver metastases in colorectal cancer].
Topics: Colorectal Neoplasms; Embolization, Therapeutic; Evaluation Studies as Topic; Hepatic Artery; Humans | 1989 |
[Study of long-survival cases with liver metastasis of colorectal cancer by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Doxo | 1989 |
[Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cholangitis, Sclerosin | 1989 |
Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro.
Topics: Azirines; Carbazilquinone; Carcinoma; Cells, Cultured; Colorectal Neoplasms; HeLa Cells; Humans; Hyp | 1989 |
[Surgery for far-advanced colorectal cancer--extension of surgical indication and its results].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Neoplasm Metastasis; | 1989 |
Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma.
Topics: Colorectal Neoplasms; Female; Floxuridine; Humans; Leukocyte Count; Liver Neoplasms; Male; Mitomycin | 1989 |
[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Com | 1989 |
[The study of transcatheter arterial chemo-lipiodol administration in liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1989 |
[Hepatic arterial infusion chemotherapy using totally implantable reservoir in liver metastases in colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoemb | 1989 |
[Rationale and current results of loco-regional chemotherapy in hepatic metastases of colorectal carcinoma].
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Colorectal Neoplasms; Doxorubicin; Floxuridine; Fluoro | 1987 |
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dos | 1988 |